



Bibliography



CHAPTER 10

BIBLIOGRAPHY

1. Abreu MT. Immunologic regulation of toll-like receptors in gut epithelium. *Current Opinion in Gastroenterology* 2003. 19: 559-64
2. Aderem A and Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. *Nature* 2000. 406: 782-87
3. Ahuja MMS. Epidemiological studies on diabetes mellitus in India. In: Ahuja MMS, editor. *Epidemiology of diabetes in developing countries*. New Delhi: Interprint; 1979 pp. 29-38
4. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL and Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. *Proceedings of National Academy of Science U.S.A* 1995. 92: 10457-10461
5. Akira S, Takeda K and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nature Immunology* 2001. 2: 675-80
6. Alberti KG and Zimmet PZ. Definition diagnosis and classification of diabetes mellitus and its complications. Part I Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. *Diabetes Medicine* 1998. 15: 539-53
7. Alexendria Va. Diabetes vital statistics. American Diabetes Association. 2001
8. Allender PS, Cutler JA, Follmann D, Cappuccio FP, Pryer J and Elliott P. Dietary Calcium and Blood Pressure: A Meta-Analysis of Randomized Clinical Trials. *Ann Intern Med* 2004. 124: 825-831
9. Alles MS et al. Consumption of fructooligosaccharide does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. *American Journal of Clinical Nutrition* 1999. 69: 64-69
10. Ambady R, Chamukuttan S, Kapur A, Vijay V, Mohan V and Das AK. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia* 2001. 44(1): 1094-1101

11. American Diabetes Association. Nutritional recommendations and principles for individuals with diabetes mellitus: 1986: American Diabetes Association. *Diabetes Care* 1987. 10: 126-132
12. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997. 20: 1183-97
13. American Diabetes Association: Standards for medical care in diabetes-2006 (Position statement). *Diabetes care* 2006. 29(S1): S43, 2006
14. American Diabetes Association: Standards of medical care in diabetes—2007 [Position Statement]. *Diabetes Care* 30: S4-S41, 2007
15. American Diabetic Association (ADA). 70th Scientific session. Journal of diabetes news. *Journal of Diabetes* 2010. 2:227-232. doi: 10.1111/j.1753-0407.2010.00097.x
16. American Diabetic Association (ADA). Report of the expert committee on the diagnosis and classification of diabetes mellitus., *Diabetes Care* 2003. 26 Suppl 1: S5-20
17. American Heart Association (AHA). Exercise training of type 2 diabetes mellitus: Impact on cardiovascular risk: A scientific statement from the AHA. *Circulation* 2009. 119:3244-3262.
18. Amos A, Mc Carty D and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. *Diabetic Medicine* 1997. 14: S1-S85
19. Anand SS, Dagenais GR, V Mohan, Diaz R, Probstfield J, Freeman R, Shaw J, Lanas F et al. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the Epi DREAM cohort study. *European Journal of Preventive Cardiology* 2012. 19(4):755-764.
20. Anderson JB and Garner CS. Algorithm content 2000. Updated by Marion J Franz, 2006. Chapter 30 Krause's food and nutrition therapy. 12th edition. Saunders Elsevier Publication 2008.
21. Anderson JW. Nutrition management of diabetes mellitus. In: Modern nutrition in Health and disease. Eds. Shils ME, Young VR, KM Vargese company, Mumbai. pp. 1201-1229. 1988

22. Andersson AF, Lindberg M, Jakobsson H, Backhed F, Nyren P and Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. *PLoS ONE* 2008. 3(7): e2836, 1_8, doi:10.1371/journal.pone.0002836.
23. Andrew LW, Delphind MA, Saulnier and Gibson GR. Gastrointestinal microflora and interactions with gut mucosa. Chapter 2. *Handbook of prebiotics* by Gibson GR and Roberfroid MB. CRC press, Taylor and Francis group USA. 2008 pp. 11-38
24. Anini Y and Brubaker PL. Muscarinic receptors control glucagon-like peptide-1 secretion by human endocrine L cells. *Endocrinology* 2003. 144:3244.
25. Arai S. Global view on functional foods: Asian perspectives. *British Journal of Nutrition* 2002. 88(2): S139-S143
26. Archer BJ, Johnson SK, Devereux HM and Baxter AL. Effect of fat replacement by inulin or lupin-kernel fibre on sausage patty acceptability, post-meal perceptions of satiety and food intake in men. *British Journal of Nutrition* 2004. 91: 591-9
27. Aryana KJ, Plauche S, Rao RM, McGrew P and Shah NP. Fat-Free Plain Yogurt Manufactured with Inulins of Various Chain Lengths and *Lactobacillus acidophilus*. *Journal of Food Science* 2007. 72(3): M79-M84
28. Asami T, Ohyama T, Minamimisawa K and Tsukihashi T. Good Feed Chem 1989. M(9): 1033
29. Aso Y, Akazan H, BPL study group. Prophylatic effect of *lactobacillus casei* preparation on the recurrence of superficial bladder cancer. *Urolo Int* 1996. 49: 125-129
30. Baba E, Nagaishi S, Fukata T, Arakawa A. The role of intestinal microflora on the prevention of *Salmonella* colonization in gnotobiotic chickens. *Poultry Sci* 1991; 70: 1902-07
31. Backhed F, Ding H, Wang T, Hooper LV, Koh GY and Nagy A et al. The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the National Academy of Sciences USA* 2004. 101(44): 15718-15723
32. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. *Science* 2005. 307: 1915-1920

33. Bäckhed F, Manchester JK, Semenkovich CF and Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proceedings of National Academy of Science USA* 2007. 104: 979-984
34. Badman MK and Flier JS. The gut and energy balance: visceral allies in the obesity wars. *Science*. 2005. 307:1909-14
35. Bakker-Z AM. Fecal SIgA secretion in infants fed on pre or probiotic infant formula. *Pediatrics Allergy Immunology* 2006. 17:134-140
36. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ and Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. *Circulation* 2008. 117:2340-50
37. Barndt RL, Liao S, Merkel CM, Chapello WJ and Navia JL. Low calorie palatable fiber containing, sugar substitute. United states patent application publication. Pub No. US 2003/0054080A1. 2003
38. Beckman JA, Creager MA and Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA* 2002. 287: 2570-2581
39. Berno Y, Sawada K and Mitsuoka T. The intestinal microflora of infants: composition of fecal flora in breast fed and bottle fed infants. *Microbiology and Immunology* 1984. 28: 975-986
40. Bernalier A, Dore J and Durand M. Biochemistry of fermentation. Gibson G., Roberfroid M. (eds) *Colonic Microbiota, Nutrition and Health*. Dordrecht:Kluwer Academic Publishers. pp. 37-53. 1999
41. Bernet MF, Brassart D, Neeser JR and Servin AL. *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by entero virulent bacteria. *Gut* 1994. 35: 483-89
42. Bernhardt H, Wellmer A, Zimmermann K and Knoke M. Growth of candida albicans in normal and altered fecal flora in the model of continuous flow culture. *Mycoses* 1995. 38: 265-270
43. Bioletto S, Golay M, Munger R, Kalix B and James RW. Acute hyperglycemia and very low density and low density lipoprotein sub-fractions in obese subjects. *American Journal of Clinical Nutrition* 2000. 71: 443-449

44. Bishay IE 1998. Rheological characterization of inulin. In: Williams, P.A. and Phillips, G.O. (Eds) Gums and stabilizers for the food industry. Cambridge, UK: Royal Society of Chemistry pp 201-210.
45. Bjorksten B. The gut microbiota: A complex ecosystem. *Clinical and Experimental Allergy* 2006. 36(10): 1215-1217
46. Blaut M and Clavel T. Metabolic diversity of the intestinal microbiota: Implications for health and disease. *Journal of Nutrition* 2007. 137: 751S-755S
47. Boden G. Free fatty acids, insulin resistance and type 2 diabetes mellitus. *Proc Assoc Am Physicians* 1999. 111: 241-248
48. Boler BV, Seroo MC, Faber TA, Bauer LL, Chow JM and Murphy MR et al. *In Vitro* Fermentation Characteristics of Select Nondigestible Oligosaccharides by Infant Fecal Inoculation. *Journal of Agriculture Food Chemistry* 2013. 61 (9): 2109-2119
49. Bonner-Weir S. Life and death of the pancreatic beta cells. *Trends Endocrinology Metabolism* 2000. 11: 375-378
50. Borkman et al 1993. Cited in Bengt Vess by. Dietary fat and insulin action in humans. *British Journal of Nutrition* 2000. 83(1): S91-S96
51. Bornet FRJ. Indigestible sugars in food products. *American Journal of Clinical Nutrition* 1994. 59: 763S-9S
52. Borrueal N, Carol M, Casellas F, et al. Increased mucosal TNF production in Crohn's disease can be down regulated *ex vivo* by probiotic bacteria. *Gut* 2002. 5: 659-64
53. Bouhnik Y et al. Short chain fructooligosaccharide administration dose dependently increases fecal bifidobacteria in healthy humans. *Journal of Nutrition* 1999. 129: 113
54. Bouhnik Y, Raskine L, Simoneau G, Vicaud E, Neut C, Flourié B, Brouns F and Bornet FR. The capacity of non-digestible carbohydrates to stimulate fecal *bifidobacteria* in healthy humans: a double blind, randomized, placebo-controlled, parallel-group, dose response relation study. *American Journal of Clinical Nutrition* 2004. 80: 1658-1664
55. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R et al. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 2005. 28: 956-962

56. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. *Am J Med* 2007. 120: S12-S17
57. Braaten JT, Wood PJ, Scott FW, Riedel D, Poste LM and Collins MW. Oat gum lowers glucose and insulin after an oral glucose load. *American Journal of Clinical Nutrition* 1991. 53: 1425-1430
58. Brennanab CS and Samyue E. Evaluation of Starch Degradation and Textural Characteristics of Dietary Fiber Enriched Biscuits. *International Journal of Food Properties* 2004. 7(3): 647-657
59. Brigenti F, Casirgahi M, Canzi E and Ferrari A. Effect of consumption of ready to eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. *European Journal of Clinical Nutrition* 1999. 53: 726-733
60. Brook I. Bacterial interference. *Critical Review of Microbiology* 1999. 25: 155-72
61. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, et al. The orphan G-protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem* 2003. 278: 11312-11319
62. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001. 414: 813-820
63. Brubaker PL and Drucker DJ. Mini-review: Glucagon like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. *Endocrinology* 2004. 145: 2653
64. Bruning JC et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. *Mol Cell* 1998. 2: 559-569
65. Buddington RK et al. Dietary supplement of neosugar alters the fecal flora and decreases activities of some reductive enzymes in human subjects. *American Journal of Clinical nutrition* 1996. 63: 709
66. Buse JB, Bergenstal RM, Glass LC et al. Use of twice daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med* 2011. 154: 103-12
67. Busserolls J et al. Oligofructose protects against the hyperlipidemic and pro-oxidative effects of a high fructose diet in rats. *Journal of Nutrition* 2003. 133: 1903

68. Buteau J, Roduit R, Susini S, and Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. *Diabetologia* 1999. 42: 856-864
69. Butler JE, Sun J, Weber P, Navarro P and Francis D. Antibody repertoire development in fetal and newborn piglets, III. Colonization of the gastrointestinal tract selectively diversifies the pre immune repertoire in mucosal lymphoid tissues. *Immunology* 2001. 100: 119-30
70. Cacicedo JM, Yagihashi N, Keaney JF, Ruderman NB and I do Y. AMPK inhibits fatty acid-induced increases in NF- κ B transactivation in cultured human umbilical vein endothelial cells. *Biochem Biophys Res Commun* 2004. 324: 1204-1209
71. Campbell JM, Bauer LL, Fahey GC, Hogarth AJ, Wolf BW and Hunter DE. Selected fructooligosaccharide (1-ketose, nystose and 1F- β -Fructofuanosylnystose) composition of foods and feeds. *Journal of Agricultural and Food Chemistry* 1997. 45: 3076-3082
72. Campbell JM, Fahey GC and Bryan WW. Selected indigestible oligosaccharides affect large bowel mass, cecal and short chain fatty acids, pH and microflora in rats. *Journal of Nutrition* 1997. 127: 130-135
73. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxaemia initiates obesity and insulin resistance. *Diabetes* 2007. 56: 1761-1772
74. Cani PD and Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. *Current Opinion in Clinical Nutrition Metabolism Care* 2007. 10: 729-734
75. Cani PD, Amar J, Iglesias MA et al., "Metabolic endotoxaemia initiates obesity and insulin resistance," *Diabetes* 2007. 56(7): 1761-1772
76. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* 2008. 57: 1470-1481
77. Cani PD, Catherine A, Daubioul CA, Brigitte B, Reusens, C, Remacle C, Grégory G Catillon, Nathalie M and Delzenne NM. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering

- effect of oligofructose in streptozotocin-treated rats. *Journal of Endocrinology* 2005. 6(1) (Abstract)
78. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G and Delzenne NM. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. *Journal of Endocrinology* 2005. 185: 457-465
79. Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. *Current Opinion in Clinical Nutrition Metabolism Care* 2007; 10: 729-734
80. Cani PD, Hoste S, Guiot Y and Delzenne MB. NGN3 and Neuro D, mRNA in the proximal colon of rats fed a control diet or a diet supplemented with OFS. *British Journal of Nutrition* 2007. 98(1): 32-37.
81. Cani PD, Joly E, Horsmans Y and Delzenne NM. Oligofructose promotes satiety in healthy human: a pilot study. *European Journal of Clinical Nutrition* 2006. 60: 567-572
82. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM and Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional GLP-1 receptor. *Diabetes* 2006. 55: 1484-1490
83. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of *bifidobacteria* in gut microflora improves high-fat diet-induced diabetes through a mechanism associated with endotoxaemia. *Diabetologia* 2007. 50: 2374-2383
84. Cani PD, Sophie S Hoste, Yves Y Guiot, Nathalie M and Delzenne NM. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. *British Journal of Nutrition* 2007. 7(1) (Abstract)
85. Cardarelli HR, Aragon-Alegro LC, Alegro JH, Castro de IA and Saad MI. Effect of inulin and *Lactobacillus paracasei* on sensory and instrumental texture properties of functional chocolate mousse. *Journal of the Science of Food and Agriculture* 2008. 88(8): 1318-1324
86. Causey JL et al. Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal, environmental in hypercholesterolemic men. *Nutrition Research* 2000. 20:191
87. Causey JL, Feirtag JM, Gallaher DD, Tungland BC and Salvin JL. Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal

- environment in hypercholesterolemic men. *Nutrition Research* 2000. 20: 191-201
88. Cavaghan MK, Ehrmann DA and Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose tolerance. *Journal of Clinical investigation* 2000. 106: 329-333
89. Cebra JJ, Periwal SB, Lee G, Lee F, Shroff KE. Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. *Dev Immunol* 1998. 6: 13-18
90. Chae-Jin Lee, Hee-Soon Cheon and Jun-Bong Choi. Fructooligosaccharide granola bar. United States patent Application. Appl. No. 12/996,233. PCT No. PCT/KR2009/003094 USCL. 426/650. 2011
91. Chang SND and Lili H. Study on Production of Xylooligosaccharides from Corn cob with Steaming and Enzymatic Hydrolysis. *Journal of the Food Industry* 2007. 1(4): pp. 5
92. Chaudhri OB, Salem V, Murphy KG and Bloom SR. Gastrointestinal satiety signals. *Annu Rev Physiol* 2008. 70: 239-55
93. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF and Shin SJ et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. *Journal of Clinical Endocrinology Metabolism* 2005. 91(1): 295- 299
94. Cheng H and Lai M. Fermentation of resistant rice starch produces propionate reducing serum and hepatic Cholesterol in Rats. *The Journal of Nutrition* 2000. 130(8): 1991-1995
95. Cicek B, Arslan P, Fahretti K: The effects of oligofructose and polydextrose on metabolic control parameters in type-2 diabetes. *Pak J Med Sci* 2009. 25: 573-578.
96. Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. *Blood* 1998. 91, 3527-3561
97. Conly JM, Stein K, Worobetz L and Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. *American Journal of Gastroenterology* 1994. 89: 915-23

98. Conterno L, Fava F, Viola R and Tuohy KM. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? *Genes Nutrition* 2011. 6: 241-60
99. Cook S and Sellin J. Short Chain Fatty Acids in Health and Disease. *Alimentary Pharmacology and Therapeutics* 1998. 12(6): 499-507
100. Coudray C, Bellanger J, Castiglia DC, Remesy C, Vermorel M, and Rayssiguier Y. Effect of soluble dietary fibers supplementation on absorption and balance of calcium, magnesium, iron and zinc in healthy young men. *European journal of Clinical Nutrition* 1997. 51: 375-380
101. Coudray C, Demigne C and Rayssiguier Y. Effects of dietary fibers on magnesium absorption in animals and humans. *Journal of Nutrition* 2003. 133:1-4
102. Coudray C, Feillet C, Gueux E, Mazur A and Rayssiguier Y. Dietary inulin intake and age affect intestinal absorption of zinc and copper in rats. *Journal of Nutrition* 2006. 136: 117-122
103. Coudray C, Rambeau M, Feillet C, Tressol JC, Deminge C and Gueux E et al. Dietary inulin intake and age can significantly affect intestinal absorption of calcium and magnesium in rats: A stable isotope approach. *Nutrition Journal* 2005. 4: 29
104. Coudray C, Tressol JC, Gueux E and Rayssiguier Y. effects of inulin type fructans of different chain length and type of branching on intestinal absorption and balance of calcium and magnesium in rats. *European Journal of Nutrition* 2003. 42: 91-98
105. Coussement P. Inulin and Oligofructose as dietary fiber: Analytical, nutritional and legal aspects. Complex carbohydrates in foods. Eastern Hemisphere Distribution Publishing group USA 1999. Chapter 16 pp. 203-204
106. Coussement P. Inulin and oligofructose: safe intakes and legal status. *Journal of Nutrition* 1999. 129: 1412S-7S
107. Coussement P. Pre- and synbiotics with inulin and oligofructose: promising developments in functional foods. *European Food Research and Technology* 1996. 102-104
108. Coxam V. Inulin-type fructans and bone health: state of the art and perspectives in the management of osteoporosis. *British Journal of Nutrition*. 2005. 93(1): S111-123

109. CRC handbook of dietary fiber in human nutrition (2nd ed.). Spiller GA, ed. Boca Raton, FL: CRC Press; 1993. pp. 1648
110. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL and Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. *American Journal of Physiology* 2007. 292: E740-E747
111. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ and Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon like peptide I (7-36) amide in type 1 diabetic patients. *Diabetes Care* 1996. 19: 580-586
112. Creutzfeldt W. Entero-insular axis and diabetes mellitus. *Horm Metab Res* 1992. 26: 13-18
113. Crittenden RG. Prebiotics. In: Tannock GW, editor. Probiotics: a critical review. Wymondham: pp. 141-156. Horizon Scientific Press. 1999
114. Cruza AG, Cavalcantia RN, Guerreiroa LMR, Sant Anac AS, Nogueirab LC and Oliveira CAF et al. Developing a prebiotic yogurt: Rheological, physico-chemical and microbiological aspects and adequacy of survival analysis methodology. *Journal of Food Engineering* 2013. 114(3): 323-330
115. Cui HH, Chen CL, Wang JD, Yang YL, Cun Y, Wu JB et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. *World of Journal of Gastroenterology* 2004. 10: 1521-1525
116. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE and Weigle DS. A pre-prandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. *Diabetes* 2001. 50: 1714-9
117. Cummings J and Macfarlane G. The Control and Consequences of Bacterial Fermentation in the Human Colon. *Journal of Applied Bacteriology* 1991. 70(6): 443-459
118. Cummings J, Roberfroid M, Andersson H, Barth C, Ferro-Luzzi A and Ghooos Y. New Look at Dietary Carbohydrate: Chemistry, Physiology and Health. *European Journal of Clinical Nutrition* 1997. 51(7) 417-423
119. Cummings J. Short Chain Fatty Acids in the Human Colon. *Gut* 1981. 22(9): 763-779

-
120. Cummings JH, Beatty ER, Kingman SM, Bingham SA and Englyst HN. Digestion and physiological properties of resistant starch in the human large bowel. *British Journal of Nutrition* 1996. 75: 733-47
 121. Cummings JH, Englyst HN. Fermentation in the human large intestine and the available substrates. *American Journal of Clinical Nutrition* 1987. 45 (suppl): 1243-55
 122. D'Alessio DA, Prigeon RL and Ensink JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide I. *Diabetes* 1995. 44: 1433-1437
 123. Dardevet D et al. Insulin secretion independent effects of glucagon-like-peptide 1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. *Am J Physiol Gastrointest Liver Physiol* 2005. 289(5): G806-G814
 124. Dastani Z, Dangoisse C, Boucher B, Desbiens K, Krimbou L, Dufour R, Hegele RA, Pajukanta P, Engert JC, Genest J, Marcil M (March 2006). "A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians". *Atherosclerosis* 2005. 185(1): 127-36
 125. Davidson MH, Synecki C, Maki KC and Drennen KB. Effects of dietary inulin in serum lipids in men and women with hypercholesterolemia. *Nutrition Research* 1998. 3: 503-517
 126. De Leenheer L. Production and use of inulin: industrial reality with a promising future. In: Van Bakkum H, Ro per H, Voragen F, editors. Carbohydrates as organic raw materials III. New York: V.C.H. Publishers. pp. 67-92. 1996
 127. Deacon CF, Johnsen AH and Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. *J Clin Endocrinol Metab* 1995. 80: 952-957
 128. DeFronzo RA, Bonadonna RC and Ferranninni E. Pathogenesis of NIDDM: a balanced view. *Diabetes care* 1992. 15: 618-368
 129. Delzenne N, Roberfroid MB. Physiological effects of nondigestible oligosaccharides. *Lebensm-Wiss Technol* 1994. 27: 1-6
 130. Delzenne NM and Kok N. Effect of non-digestible fermented carbohydrates on hepatic fatty acid metabolism. *Biochemical Society Transactions* 1998. 26: 228-230
-

131. Delzenne NM and Kok N. Effects of fructans-type prebiotics on lipid metabolism. *American Journal of Clinical Nutrition* 2001. 73: S456
132. Delzenne NM, Daubioul A, Neyrinck ML and Taper HS. Inulin and oligofructose modulate lipid metabolism in animals: review of biochemical events and future prospects. *British journal of Nutrition* 2002. 87(2): S255-S259
133. Delzenne, N and Kok NN. Dietary fructooligosaccharides modify lipid metabolism in the rat. *Journal of Nutrition* 1999. 129: 1467S- 1469S
134. Demigne C, remesy C and Morand C. Short chain fatty acids. In: colonic microbiota, nutrition and health, edited by Gibson GR et al. pp. 55-63. Kluwer Academic Publishers, The Netherlands. 1999
135. Demigne C, Ronald C, Levart MA, Bessen C, Moundras C and Remesey C. Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. *British Journal of Nutrition* 1995. 74: 209-219
136. Deo SS, Zantye A, Mokal R, Mithbawkar S, Rane S and Thakur K. To identify the risk factors for high prevalence of diabetes and impaired glucose tolerance in Indian rural population. *Int J Diab Dev Ctries* 2006. 26: 19-23
137. Desai S and Mani UV. Aberrations in lipid profile in relation to BMI and WHR: A population based survey in an industrial set up in Baroda, Gujarat, India. *Ann Nutr Metab* 2001. 45(1): 230
138. Dethlefsen L, Huse S, Sogin ML and Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol* 2008. 6(11): 2383-2400
139. Dewulf EM, Cani PD, Neyrinck AM, et al. Inulin type fructans with prebiotic properties counteract GPR43 overexpression and PPAR gamma-related adipogenesis in the white adipose tissue of high-fat diet fed mice. *J Nutr Biochem* 2011 (Epub ahead of print).
140. Dhurandhar NV, Kulkarni PR. Prevalence of obesity in Bomaby. *Int J Obes Relat Metab Disor* 1992. 16: 367-75
141. Diamant M, Blaak EE and de Vos WM. Do nutrient-gut-microbiota interactions play a role in himan obesity, insulin resistance and type 2 diabetes. *Obesity reviews* 2011. 12(4): 272-281

-
142. Dieleman LA, Goeress MS, Arends A, Sprengers D, Torrice C, Hoentjen F, Grether WB, Sartor RB. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. *Gut* 2003. 52: 370-376
 143. Ding WG and Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. *Diabetes* 1997. 46: 615-621
 144. Donkor ON, Henriksson A, Vasiljevic T and Shah NP. Probiotic strains as starter cultures improve angiotensin-converting enzyme inhibitory activity in soy yogurt. *Journal of Food Science* 2005. 70: M375-381
 145. Douwina B, Micheline Van CB, Rudy VC and Hendrik D. Availabilities of calcium, iron, and zinc from dairy infant formulas is affected by soluble dietary fibers and modified starch fractions. *Nutrition* 2003. 07-01
 146. Druce MR, Small CJ and Bloom SR. Mini-review: Gut peptides regulating satiety. *Endocrinology* 2004. 145: pp-2660
 147. Du XL, Edelstein D, Rossetti L et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci U.S.A.* 2000. 97: 12222-12226
 148. Duncan SH, Louis P and Flint HJ 2007. Cultivable bacterial diversity from the human colon. *Lett Appl Microbiol* 44: 343-350
 149. Dupre J, Behme MT, Hramiak IM, Mc-Farlane P, Williamson MP, Zabel P, Mc-Donald TJ: Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM. *Diabetes* 1995. 44: 626-630
 150. Dupre J, Ross SA, Watson D, and Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. *J Clin Endocrinol Metab* 1973. 37: 826-828
 151. Eckburg PB, Bik EM, Bernstein CN et al., "Diversity of the human intestinal microbial flora," *Science* 2005. 308(5728): 1635-1638
 152. Eduardo Estevea,b, Wifredo Ricarta,b and Jose-Manuel Ferná'ndez-Real. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? *Current Opinion in Clinical Nutrition and Metabolic Care* 2011, 14: 483-490
-

-
153. Egan JM, Bulotta A, Hui H, and Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. *Diabetes Metab Res Rev* 2003. 19: 115-123
 154. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessles RC. Trends in alternative medicine use in the United States, 1990-1997: Result of follow-up national survey. *JAMA* 1998. 280: 1569-1575 (Abstract)
 155. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF and Andersen DK: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. *Regul Pept* 1994. 51: 63-74
 156. Eliasson B, Gorde-Moller D, Olofsson-Eeg K, Wilson C, Cederholm J and Fleck P et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. *Diabetologia* 2012. 55(4): 915-925
 157. Elmer GW, Surawicz M, McFarl and LV. Biotherapeutic Agents: Review, a neglected modality of the treatment and prevention of selected intestinal and vaginal infections. *J Am Med Assoc* 1996. 275(11):870-876
 158. Espinos M and Rico E. Low Molecular Weight Carbohydrates in Foods Usually Consumed in Spain. *Food Science and Technology International* 2006. 12 (2): 171-175
 159. Esteve E, Ricart, Wifreso, Fernandez R and Jose M. Gut microbiota interactions with obesity insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance. *Current Opinion in Clinical Nutrition & Metabolic Care* 2011. 14(5): 483-490.
 160. Evelyne M and Nicolas G. Fn-type Chicory Inulin Hydrolysate Has a Prebiotic Effect in Humans. *The Journal of Nutrition* 2000. 130(5): 1197-1199
 161. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. *Dan Med Bull* 1999. 46: 183-96
 162. FAO/WHO Expert Consultation. Report of a joint FAO/WHO Expert Consultation. Health and nutritional properties of probiotics in food including powder milk and live lactic acid bacteria, 2001. Ref Type: Report, (ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf) 2010
 163. Farilla L et al. GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology* 2003. 144: 1549
-

-
164. Farnworth ER. Fructans in human and animal diets, In: Suzuki M, Chatterton NJ, editors. Science and technology of fructans. Boca Raton, FL: CRC Press; 1993. pp. 258–70
 165. Farzanmehr H and Abbasi S. Effects of inulin and bulking agents on some physicochemical, textural and sensory properties of milk chocolate. *Journal of Texture Studies* 2009. 40(5): 536–553
 166. Fava F, Lovegrove R, Gitau K, Jackson KG and Tuohy K. The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. *Current Medical Chemistry* 2006. 13: 3005–3021
 167. Fehmann HC and Habener JF. Insulinotropic hormone glucagon-like peptide-I (7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. *Endocrinology* 1992. 130: 159–166
 168. Fehmann HC, Goke R, and Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. *Endocrinology Reviews* 1995. 16: 390–410
 169. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM and Kingwell BA. Intensive Cholesterol Reduction Lowers Blood Pressure and Large Artery Stiffness in Isolated Systolic Hypertension. *J Am Coll Cardiol* 2002. 39: 1020–1025
 170. Fiordaliso M, Kok N, Desager JP, Goethaks F, Deboyser D, Roberfroid M and Delzenne N. Dietary oligofructose lowers triglyceride, phospholipid and cholesterol in serum and very low density lipoproteins of rats. *Lipids* 1995. 30(2): 163–167
 171. Flamm G, Glinsmann W, Kritchevsky D, Prosky L and Roberfroid M. Inulin and Oligofructose as Dietary Fiber: A Review of Evidence. *Critical Reviews in Food Science and Nutrition* 2001. 41(5): 353–362
 172. Flint HJ, Bayer EA, Rincon MT, Lamed R and White BA. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. *Nature Rev Microb* 2008. 6: 121–131
 173. Flint HJ. The significance of prokaryote diversity in the human gastrointestinal tract. In *Prokaryotic Diversity: Mechanisms and Significance*. Logan, N.A. Lappin-Scott, H.M., and Oyston, P.C.F. (eds). Cambridge, UK: Cambridge University Press, pp. 65–90. 2006
-

-
174. Folly de G, Silva da EN, Verner FV, Silva dos F and Volp and CP. Acceptance of handmade products containing nuts and fructooligosaccharides. *Nutrition hospitalaria* 2013. 28(1): 86-92
 175. Fong DS, Aiello LP, Ferris FL and Klein R: Diabetic retinopathy. *Diabetes Care* 2004. 27: 2540-2553
 176. Fooks LJ and Gibson GR. Probiotics as modulators of the gut flora. *British journal of Nutrition* 2002. 88: S39-S49
 177. Forcheron F and Beylot M. Long-term administration of inulin-type fructans has no significant lipid-lowering effect in normo lipidemic humans. *Metab Clin Exp* 2007. 56: 1093-8
 178. Fossati P and Prencipe L. Serum Triglycerides Determined Calorimetrically with an Enzyme That Produces Hydrogen Peroxide. *Clinical Chemistry* 1982. 28(10): 2077-2080
 179. Franck A and Coussement P. Multi-functional inulin. Food Ingredients and Analysis International, October, 8-10. 1997
 180. Franck AM. Inulin and oligofructose. In: Gibson GR and Angus F (Eds) LFRA ingredient handbook: Prebiotics and probiotics. p. 1-18. Surrey: Leatherhead Publishing. 2000
 181. Frank B, Manson JE, Stamfer MJ and Colditz G. Diet, lifestyle and risk of type 2 diabetes in women. *N Eng J of Med* 2001. 345 (11): 790-797
 182. Franz MJ, Bantle JP et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 2002. 25: 148-98
 183. Freitas Folly GA, Neiva da Silva E, Verner FA, Silva FC and Pinheiro Volp CA. Acceptance of handmade products containing nuts and fructooligosaccharides. *Nutricion Hospitalaria* 2013. 28(1): 86-92
 184. Freter R. Mechanism of bacterial colonization of the mucosal surfaces of the gut. Virulence of mechanisms of bacterial pathogens. American society of microbiology, Washington DC, pp. 45-60. 1998
 185. Fujisawa T, Benno Y, Yaeshima T and Mitsouka T. Taxonomic study of the *Lactobacillus acidophilus* group, with recognition of *Lactobacillus gallinarum* sp-nov and *Lactobacillus johnsonii* sp-nov and synonym of *Lactobacillus acidophilus* Group A3 (Johnson et al 1980) with the type strain of *Lactobacillus*
-

- amylovorus* (Nakamura 1981). *International Journal of Systematic Bacteriology* 1992. 42(3): 487-491
186. Fuller R. Probiotics in man and animals. *The Journal of applied bacteriology* 1989. 66(5): 365-378
187. Furrie E et al. Synbiotic therapy (*Bifidobacterium longum*/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomized controlled pilot trial. *Gut* 2006. 54: 242-249
188. Furrie E, Mcfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA et al. Synbiotic therapy initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. *Gut* 2005. 54: 242-249
189. Gabbay KH: Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? *Curr Diab Rep* 2004. 4: 405-408
190. Gallagher E, Brein CMO, Scannell AGM and Arendt EK. Use of response surface methodology to produce functional short dough biscuits. *Journal of Food Engineering* 2003. 56(2-3): 269-271
191. Gallaher DD, Gallaher CM, Mahrt GJ, Carr TP, Hollingshead CH, Hesslink RJ and Wise JA. Glucomannan and Chitosan Fiber Supplement Decreases Plasma Cholesterol and Increases Cholesterol Excretion in Overweight Normo cholesterolemic Humans. *J Am Coll Nutr* 2002. 21: 428-433
192. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT and Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes* 2009. 58: 1509-1517
193. García AH and Lopez G. Metabolism of Short Chain Fatty Acids in the Colon and Faeces of Mice after a Supplementation of Diets with Agave Fructans. *Lipid metabolism*, chapter 8, pp. 163-182. 2013 <http://dx.doi.org/10.5772/51248>.
194. Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. *Diabetes* 2003. 52: 453-62
195. Gaudier E, Michel C, Segain JP, Cherbut C and Hoebler C. The VSL probiotic mixture modifies microflora but does not heal chronic dextras sodium sulfate-induced colitis or reinforce the mucus barrier in mice. *Journal of Nutrition* 2005. 135: 2753-2761.

-
196. Georg P and Ludvik B. Lipids and diabetes, *Journal of Clinical Basic Cardiology* 2000. 3: 159-62
 197. Giacco R, Clemente G, Luongo D, Lasorella G, Fiume I, Brouns F et al. Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. *Clinical Nutrition* 2004. 23(3): 331-40
 198. Gibson GR and Delzenne N. Inulin and oligofructose: new scientific developments. *Nutrition Today* 2008. 43(2): 54-59
 199. Gibson GR and Mac Farlane GT. Intestinal bacteria and disease. In Gibson, S.A.W., ed. *Human Health: The Contribution of Microorganisms*. London, UK: Springer-Verlag; 53- 62. 1994
 200. Gibson GR and Roberfroid MB. Dietary modulation of the human colonic microbiota-introducing the concept of prebiotics. *Journal of Nutrition* 1995. 125:1401-1412
 201. Gibson GR and Roberfroid MB. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutrition Research Review* 1995. 125: 1401-1412
 202. Gibson GR and Wang X. Enrichment of bifidobacteria from human gut contents by oligofructose using continuous culture, FEMS. *Microbiology letters* 1994. 118:121
 203. Gibson GR, Probert HM, Van loo JAE, Rastall RA and Roberfroid MB. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutrition Research Review* 2004. 17:259-275
 204. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *Journal of Nutrition* 1995. 125:1401-12
 205. Gibson GR. Dietary Modulation of the Human Gut Microflora Using the Prebiotics Oligofructose and Inulin. *The Journal of Nutrition* 1999. 129(7) 1438S-1441
 206. Gibson PR, Moeller I, Kagelari O, Folino M and Young GP. Contrasting effects of butyrate on the expression of phenotypic markers of differentiation in neoplastic and non-neoplastic colonic epithelial cells in vitro. *J Gastroenterol Hepatol* 1992. 7: 165-72
-

-
207. Gibson R and Roberfroid MB. Dietary modulation of the human colonic microbiota-Introducing the concept of prebiotics. *Journal of Nutrition* 1995. 125(6): 1401-1412
208. Gill SR, Pop M, Deboý RT, Eckburg PB, Turnbaugh PJ, Samuel BS. Metagenomic analysis of the human distal gut microbiome. *Science* 2006. 312: 1355-59
209. Gilliland SE, Nelson CR and Mazwell C. Assimilation of cholesterol by *Lactobacillus acidophilus*. *Applies and Environmental Microbiology* 1985. 49: 377-381
210. Giovanni M, Roberto G and Maurizio C. Obesity, Diabetes and gut microflora: the hygiene hypothesis expanded? *Diabetes Care* 2010. 33: 2277-2284
211. Golpon HA, Puechner A, Welte T, Wichert PV and Feddersen CO. Vasorelaxant effect of glucagon-like peptide (7-36) amide and amylin on the pulmonary circulation of the rat. *Regul Pept.* 2001. 102: 81-86
212. Gonzalez EL, Johansson S, Wallander MA and Rodriguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. *J Epidemiol Community Health* 2009. 63: 332-6
213. Gopalan C. Obesity in the urban middle class. *NFI Bull*; 19: 1-4. 1998
214. Gopinath N, Chadha SL, Jain P, Shekawat S and Tandon R. An epidemiological study of obesity in adults in the urban population of Delhi. *J Assoc Physicians India* 1994. 42: 212-5
215. Gordon JL, Hooper LV, McNevin MS, Wong M and Bry L. Epithelial cell growth and differentiation. III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. *Am J Physiol* 1997. 273: G565-70
216. Goycheva P, Gadjeva V and Popov B. Oxidative stress and its complications in diabetes mellitus. *Trakia J of Science* 2006. 4(1): 1-8
217. Graier WF, Grubenthal I, Dittrich P, Wascher TC and Kostner GM. Intracellular mechanism of high d-glucose-induced modulation of vascular cell proliferation. *European Journal of Pharmacology* 1995. 294: 221-229
218. Griffin IJ and Abrams SA. Methodological considerations in measuring human calcium absorption: relevance to study the effects of inulin-type fructans. *Br J Nutr* 2005. 93: Suppl 1: S105-10.
-

219. Griffin IJ, Hicks PMD, Heaney RP, Abrams SA. Enriched chicory inulin increases calcium absorption in girls with lower calcium absorption. *Nutr Res* 2003. 23: 901-9
220. Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D and Ogra PL. *In vivo* effects of *bifidobacteria* and *lactoferrin* on gut endotoxin concentration and mucosal immunity in Balb/c mice. *Dig Dis Sci* 2004. 49: 579-589
221. Grill JP, ManiginotDurr C, Schneidar F and Ballongue J. *Bifidobacteria* and probiotic effects; action of *Bifidobacterium* species on conjugated bile salts. *Current Microbiology* 1995. 31: 23-27
222. Gromada J, Holst JJ, and Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. *Pflugers Arch* 1998. 435: 583-594
223. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH and Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. *Diabetes Care* 2005. 28: 164-176
224. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. *J Pediatr Gastroenterol Nutr* 2000. 30: 54-60
225. Guarino A, Canani RB, Spagnuolo MI, Albano F and Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. *J Pediatr Gastroenterol Nutr* 1997. 25: 516-19
226. Guarner F and Malagelada JR. Gut flora in health and disease. *Lancet* 2003. 36: 512-519
227. Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal? *Current Opinion in Gastroenterology* 2005. 21: 414-418
228. Guilherme A et al. Perinuclear localization and insulin responsiveness of GLUT4 requires cytoskeletal integrity in 3T3-L1 adipocytes. *J Biol Chem* 2000. 275: 38151-38159
229. Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP and Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. *Diabetes Res Clin Pract* 2003. 6 : 69-76

-
230. Gupta OP, Dave DM and Raval MD. A study of the prevalence of diabetes mellitus, by means of house to house survey in Ahmedabad (Gujarat) India. *Excerpt Med Intern Cong Series* 1970. 221: 47-51
231. Gupta R and Misra A. Type 2 Diabetes in India: Regional disparities. *The British journal of Diabetes and Vascular diseases* 2007. 7(1): 12-16
232. Gutzwiller JP, Drewe J, Coke B and Schmidt H et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. *The American journal of Physiological* 1999. 276(5): 1541-1544
233. Gutzwiller JP, Hruz P, Huber AR et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. *Digestion*. 2006. 73: 142-50
234. Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat Med* 2003. 9: 294-299
235. Handa C, Goomer S and Siddhu A. Effects of Whole-Multigrain and Fructooligosaccharide Incorporation on the Quality and Sensory Attributes of Cookies. *Food Sci Technol Res* 2011. 17 (1): 45 - 54
236. Handan K and Robert W Hutkins. Fermentation of Fructooligosaccharides by *Lactic acid bacteria* and *bifidobacteria*. *Appl Environ Microbiol* 2000. 66(6): 2682-2684
237. Hansen L et al. Glucagon like peptide-1-(7-36 amide) is transformed to GLP-1-(9-36 amide) by DPP-IV in the capillaries supplying L cells of the porcine intestine. *Endocrinology* 1999. 140, 5356
238. Harmsen HJ, Raangs GC, He T, Degener JE and Welling GW. Extensive set of 16S rRNA based probes for detection of bacteria in human feces. *Appl Environ Microbiol* 2002. 68: 2982-2990
239. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. *J Pediatr Gastroenterol Nutr* 2000. 30: 61-67
240. Harris K, Kassis A, Major G and Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? *Journal of Obesity*. doi:10.1155/2012/879151. pp. 1-14. 2012
241. Hartemink R and Rombouts FM. Gas formation from oligosaccharides by the intestinal microflora. *Proc. International Symposium Non-digestible*
-

- Oligosaccharides: Healthy food for the Colon?*, Wageningen, NL. pp.57-66. 1997
242. Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y and Takano T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *Am J Clin Nutr* 1996. 64: 767-771
243. Heideman et al. DiAlert: a prevention program for overweight first degree relatives of type 2 diabetes patients: results of a pilot study to test feasibility and acceptability. *Trials* 2012, 13:178 pp 1-11.
<http://www.trialsjournal.com/content/13/1/178>
244. Heijnen AM, Brink EJ, Lemmens Ag and Beynen AC. Ileal pH and apparent absorption of magnesium in rats fed on diets containing either lactose or lactulose. *British Journal of Nutrition* 1993. 70: 747-756
245. Helgeland L, Vaage JT, Rolstad B, Midtvedt T and Brandtzaeg P. Microbial colonization influences composition and T-cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine. *Immunology* 1996. 89: 494-501
246. Hidaka H, Tashiro Y and Eida T. Proliferation of bifidobacteria by oligosachharides and their useful effect on human health; *Bifidobacteria. Microflora* 1991. 10: 65-79
247. Hill MJ. Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 1997. 6 (suppl): S43-45
248. Hirata K, Kume S, Araki S et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. *Biochem Biophys Res Commun* 2009. 380: 44-9
249. Hogarth AJ, Hunter DE, Jacobs WA, Garleb KA and Wolf BW. Ion chromatographic determination of three fructooligosaccharide oligomers in prepared and preserved foods. *Journal of Agricultural and Food Chemistry* 2000. 48: 5326-5330
250. Holloway L, Moynihan S, Abrams SA, Kent K, Hsu AR and Friedlander AL. Effects of oligofructose-enriched inulin on intestinal absorption of calcium and magnesium and bone turnover markers in postmenopausal women. *British Journal of Nutrition* 2007. 97: 365-72
251. Holst JJ. Commentary. Incretin based therapies: Do they hold their promise? *Journal of Diabetes* 2012. 4: 4-7

-
252. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. *Science* 2001. 291: 881-84
 253. Hooper LV, Xu J, Falk PG, Midtvedt T and Gordon JI. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. *Proc Natl Acad Sci USA* 1999. 96: 9833-38
 254. Hosono A and Tono-oka T. Binding of cholesterol with lactic acid bacterial cells. *Milchewissenschaft* 1991. 50: 556-560
 255. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 2006. 444: 860-867
 256. Hu FB, Dam van RM and Liu S. Diet and risk of type II diabetes: the role of types of fats and carbohydrates. *Diabetologia* 2001. 44: 805-817.
 257. Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett WC, Speizer FE and Manson JE. Walking compared with vigorous physical activity and risk of type2 diabetes in women: a prospective study. *The Journal of the American Medical Association* 1999. 282(15): 1433-1439.
 258. Hylemond PB. Metabolism of bile acids in intestinal microflora. In: Daniel H, Sjovall J editors. *Sterols and Bile acids*: 331-343. Elsevier Science Publishing Inc, New York
 259. Ichikawa H et al. gastric or rectal instillation of short chain fatty acids stimulates epithelial cell proliferation of small and large intestine in rats. *Dig Dis Sci* 2002. 47: 1141-1146.
 260. Ichikawa H, Kuroiwa T, Inagaki A, Shineha R, Nishihira T, Satomi S and Sakata T. Probiotic bacteria stimulate gut epithelial cell proliferation in rat. *Digestive disease and sciences* 1999. 44: 2119-2123
 261. IDF diabetes atlas, 4th ed. International Diabetes Federation. Reddy KS. *Bull world health organ* 2009. 84, 461-469
 262. International Diabetes Federation (IDF) , IDF Diabetes Atlas, 5th ed. © 2012
 263. International Diabetes Federation. IDF Diabetes Atlas,. Brussels, Belgium: International Diabetes Federation. 4th ed. 2009
 264. International Diabetic Federation (IDF). Factsheet on diabetes, 4th ed. 2011
 265. Iyer UM, Mani I and Mani UV. Serum biochemical changes in insulin dependent and non-insulin dependent diabetes mellitus and their role in the development of secondary complications. *Int J Diab Dev Count* 1996. 16: 78-83
-

-
266. Jackson KG, Taylor GRJ, Clohessy AM and Williams CM. The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. *British Journal of Nutrition* 1999. 82: 23-30
267. Jakus V. The role of free radicals, oxidative stress and antioxidant systems in diabetes vascular disease. *Bratish Lek Listy* 2000. 101: 541-555
268. Janer C, Rohr LM, Pelaez C, Laloi M, Cleusix V, Requena et al. Hydrolysis of oligofructose by recombinant β -fructosidase from *Bifidobacterium lactis*. *System Applied Microbiology* 2004. 27: 279-285
269. Jiang HQ, Bos NA and Cebra JJ. Timing, localization, and persistence of colonization by segmented filamentous bacteria in the neonatal mouse gut depend on immune status of mothers and pups. *Infect Immun* 2001. 69: 3611-17
270. Johnson JL, Phelps CF, Cummins CS. London J, Gasser F. Taxonomy of the *Lactobacillus acidophilus* group. *International Journal of Systematic Bacteriology* 1980. 30(1): 53-68
271. Jonker TG, Smit WA, Hammer S, Snel M, Meer der RW, Lamb JH et al. Dietary modulation of plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. *American Journal of Clinical Nutrition* 2013. 97(2): 255-260
272. Joshi SR. Metabolic syndrome-emerging clusters of the Indian phenotype. *Journal of Association of Physicians of India* 2003. 51: 445- 446
273. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C and Gordon JL. Energy-balance studies reveal associations between gut microbes caloric load and nutrient absorption in humans. *American Journal of Clinical Nutrition* 2011. 94(1): 58-65
274. Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. *J Clin Invest* 1997. 100: 6-10
275. Karaki S, Mitsui R, Hayashi H, Kato I, Sugiya H, Iwanaga T, Furness JB and Kuwahara A. SCFA receptor GPR43 is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. *Cell Tissue Res* 2006. 324: 353-360
276. Karaki SI et al. Short chain fatty acid receptor, GPR43 is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. *Cell Tissue Research* 2006. 324: 353-360
-

-
277. Karpinen S et al. *In vitro* fermentation of polysaccharide of rye, wheat and oat brans and inulin by human fecal bacteria. *Journal of Science Food and Agriculture* 2000. 80: 1469
278. Katie A Meyer, Lawrence H Kushi, David R Jacobs Jr, Joanne Slavin, Thomas A Sellers and Aaron R Folsom. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. *Am J Clin Nutr* 2000. 71: 921-30
279. Kaufhold J and Hammon HM. Fructo-Oligosaccharide Supplementation: Effects on Metabolic, Endocrine and Hematological Traits in Veal Calves. *Journal of Veterinary Medicine* 2001. 47(1): 17-29
280. Kaur N and Gupta K. Applications of inulin and oligofructose in health and nutrition. *Journal of Biosciences* 2002. 27 (7): 703-14
281. Kawamata Y, Fujii R, Hosoya M et al. A G protein coupled receptor responsive to bile acids. *J Biol Chem* 2003. 278: 9435-40
282. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, Orchard TJ, Aiello LP and King GL: Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. *Diabetes Care* 2007. 30: 1995-1997
283. Kiebling G, Schneider J, Jahreis G. Longterm consumption of fermented dairy products over 6 months increases HDL cholesterol. *Eur J Clin Nutr* 2002. 56: 843-849
284. Kim M and Shin HK. The water-soluble extract of chicory reduces glucose uptake from the pefrused jejunum in rats. *J Full* 1996. 126: 2236-2242
285. Kimura K, Mc Cartney AL, Mc Connell MA and Tannock GW. Analysis of fecal populations of bifidobacteria and lactobacilli investigation of the immunological responses of their human hostes to the predominant strains. *Applied and Environment Microbiology* 1997. 63: 3394-3398
286. King H, Aubert R and Herman W. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. *Diabetes Care* 1998. 21: 1414-1431
287. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and non-diabetic subjects. *Diabetes* 2003. 52: 380-386
288. Klip A and Paquet MR. Glucose transport and glucose transporters in muscle and their metabolic regulation. *Diabetes Care* 1990. 13: 228-243
-

289. Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, et al. Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. *Diabetes* 2008. 57: 2603-12
290. Koda J, Young A, Timothy R, Beaumont K. Structure of biology of amylin. *Trends in Pharmacological Sciences* 1992. 14(4): 113-18
291. Kofler S, Nickel T and Weis M. The role of cytokines in cardiovascular diseases: focus on endothelial response to inflammation. *Clin Sci* 2005. 108: 205-213
292. Koivisto VA and Yki-Jarvinen H. Fructose and insulin sensitivity in patients with type 2 diabetes. *J Intern Med* 1993. 233: 145-53
293. Kok NN, Morgan LM and Williams CM, Roberfroid MB, Thissen JP and Delzenne NM. Insulin, GLP-1, GIP and IGF-I as putative mediators of the hypolipidemic effect of oligofructose in rats. *J Nutr* 1998. 128: 1099-1103
294. Kolbye AC, Blumenthal H, Bowman B, Byrne J, Carr CJ, Kirschman JC, Roberfroid MB and Weinberger MA. Evaluation of the Food Safety Aspects of Inulin and Oligofructose—GRAS Determination. *Orafti internal report*. Orafti, Tienen, Belgium, 1992
295. Kolida S, Meyer D, Gibson GR. A double-blind placebo controlled study to establish the *bifidogenic* dose of inulin in healthy humans. *Eur J Clin Nutr* 2007. 61: 1189-1195
296. Kolligs F, Fehmann HC, Goke R, and Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. *Diabetes* 1995. 44: 16-19
297. Korner J, Leibel RL. To eat or not to eat – How the gut talks to the brain. *N Engl J Med* 2003. 349:926-8
298. Korus J, Achremowicz KG and Sabat R. Influence of Prebiotic Additions on the Quality of Gluten-free Bread and on the Content of Inulin and Fructooligosaccharides. *European Food Research and Technology* 2012. 235(3): 545-554
299. Krauss RM, Eckel RH, Howard B, Appel LJ, Kris-Etherton P, Goldberg U, Kotchen TA et al. AHA dietary guidelines. Revisions. A statement for health care professionals from the nutrition committee of the AHA. *Circulation* 2000. 102: 2296-2311

300. Kreymann B, Ghatel MA, Williams G and Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. *Lancet* 1987. 2: 1300-1304
301. Krinos CM, Coyne MJ, Weinacht KG, Tzianabos AO, Kasper DL and Comstock LE. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. *Nature* 2001. 414: 555-58
302. Kruger CL. Agency Response Letter GRAS Notice No. GRN 000118. *CFSAN/Office of Food Additive Safety* May 5, 2003
303. Kuchbacher T, Ou SJ, Helwig U, Mimura T, Rizzello F, Klessen B et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. *Gut* 2006. 55: 833-841
304. Kuichi K, Nejima J, Takano T, Ohta M and Hashimoto H. Increased serum concentration of advanced glycation end products: a marker of coronary heart disease activity in type 2 diabetic patients. *Heart* 2001. 9: 85-87
305. Kulkarni RN et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell* 1999. 96: 329-339
306. Kulz E. Deitrag zur path toecap der diabetes. *Jahrb Tierchem* 1874. 4:448
307. Kumar BS, Krishnanb S, Kumar A, Kaushal KR, Krishna M, Kumar BB, Gupta AK. Antidiabetic activity and molecular docking of fructooligosaccharides produced by *Aureobasidium pullulans* in poloxamer-407-induced T2DM rats. *Food Chemistry* 2013. 136(2): 813-821
308. Kumar SN and Mani UV. Studies on the impact of nutrition health promotion programme in an industrial set up (DEAR) study and supplementation of *Gymnemasylvestre* In type 2 diabetic patients. PhD thesis. Dept. of Foods and Nutrition, The M.S. University of Baroda. July 2010.
309. Kumawat M , Singh I , Singh N , Singh V and Kharb S. Lipid Peroxidation and Lipid Profile in Type II Diabetes Mellitus. *Webmed Central Biochemistry* 2012. 3(3): WMC003147
310. Kun-San Xiang, Nancy J. Cox, Nancy Sanz, Peggy Huang, John H. Karam, and Graeme I. Bell. Insulin-Receptor and Apolipoprotein Genes Contribute to Development of NIDDM in Chinese Americans. *Diabetes* 1989. 38: 17-23
311. Kurokawa K, Itoh T, Kuwahara T, Oshima K, Toh H and Toyoda, A. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. *DNA Res* 2007. 14: 169-181

-
312. Kwiterovich PO. The metabolic pathways of high density lipoprotein, low density lipoprotein and triglycerides: a current review. *Am J Cardio* 2000. 86: 5-10
313. L Kathleen Mahan and Sylvia Escott-Stump. Medical nutrition therapy for diabetes mellitus and hypoglycemia of non-diabetic origin. Chapter 30. *Krause's Food and nutrition Therapy*. Saunders Elsevier publication. ISBN 978-4160-3401-8. pp. 764-809. 2008
314. Lairon D, Arnault N, Bertrais S, Planells R, Clero E, Hercberg S and Boutron RMC. Dietary Fiber Intake and Risk Factors for Cardiovascular Disease in French Adults. *Am J ClinNutr* 2005. 82: 1185-1194
315. Langlands SJ, Hopkins MJ, Coleman N and Cummings JH. Prebiotics carbohydrates modify the mucosa associated microflora of the human large bowel. *Gut* 2004. 53: 1601-1616
316. Larissa FVP, Fabiana RS and Silva ACC. Sensory profile and preference mapping of orange cakes with addition of prebiotics inulin and oligofructose. *Food Science and Technology* 2012. 41(1): 37-42
317. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreassen AS and Pedersen BK. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PLoS One* 2010. 5(2): 9085
318. Larsen PJ, Fledelius C, Knudsen LB and Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. *Diabetes* 2001. 50: 2530-2539
319. Lauer E and Kandler O. DNA-DNA homology, murein types and enzyme patterns in the type strains of the genus *Bifidobacterium*. *Systematic and Applied Microbiology* 1993. 4(1): 42-64
320. Le Blay G et al. Prolonged intake of fructooligosaccharide induces a short term elevation of lactic-acid producing bacteria and a persistent increase in cecal butyrate in rats. *Journal of Nutrition* 1999. 129: 2231
321. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME et al. Functional characterization of human receptors for SCFAs and their role in polymorphonuclear cell activation. *J BiolChem* 2003. 278: 25481-25489
322. Lessin WJ, Catigani GL and Schwartz SJ. *J Agric Food Chem* 1997. 45, 3728
-

323. Letexier D, Diraison F and Beylot M. Addition of inulin to a moderately high carbohydrate diet reduce hepatic lipogenesis and plasma triglycerol concentrations in humans. *American Journal of Clinical Nutrition* 2003. 77: 559
324. Levrat MA, Remesy C, Demigne C. Influence of inulin on urea and ammonia nitrogen fluxes in the rat cecum: consequences on nitrogen excretion. *J Nutr Biochem* 1993. 4: 1-6
325. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD and Gordon JL. Obesity alters gut microbial ecology. *Proc Natl Acad Sci USA* 2005. 102: 11070–11075
326. Ley RE, Turnbaugh PJ, Klein S and Gordon JI 2006. Microbial ecology: Human gut microbes associated with obesity. *Nature* 444: 1022-1023
327. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. *J Biol Chem* 2003. 278: 471–478
328. Licht T, Hansen M, Poulsen M and Dragsted L. Dietary Carbohydrate Source Influences Molecular Fingerprints of the Rat Faecal Microbiota. *BMC Microbiology* 2006. 6(1): 98-107
329. Lievin V, Peiffer I, Hudault S, et al. *Bifidobacterium* strains from resident infant human gastrointestinal microflora exert antimicrobial activity. *Gut* 2000. 47: 646–52
330. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Hassi HO, Rayment N et al. Clinical microbiological and immunological effects of fructooligosaccharide in patients with crohn's disease. *Gut* 2006. 55: 348-355
331. Link-Amster H, Rochat F, Saudan KY, Mignot O and Aeschlimann JM. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. *FEMS Immunol Med Microbiol* 1994. 10: 55–63
332. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD and Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. *CardiovascDiabetol.* 2010. 9: 32
333. Lopez HW et al. Class II resistant starches lower plasma and liver lipids and improve mineral retention in rats. *Journal of Nutrition* 2001. 131: 1283
334. Lopez HW, Coudray C, Levrat-Verny MA, Feillet-Coudray C, Demigne C and Remesy C. Fructooligosaccharide enhances mineral apparent absorption and

- counteract the deleterious effect of phytic acid on mineral homeostasis in rats. *Journal of Nutrition Biochemistry* 2000. 11: 500-508
335. Lorraine N, Foster A, Ananat VA and William E. Quantifying resistance starch, beta glucan and FOS in Indian and Canadian varieties of *chapati*. Virginia tech electronic theses and dissertations. Mater's theses. 2011. <http://hdl.handle.net/10919/10174>.
336. Louis P and Flint HJ. Diversity, metabolism and microbial ecology of butyrate producing bacteria from the human large intestine. *FEMS Microbiol Lett* 2009. 294: 1-8
337. Lovegrove JA. CVD risk in South Asians: the importance of defining adiposity and influence of dietary polyunsaturated fat. Symposium on 'Nutrition intervention in high risk groups'. *Proceedings of Nutrition Society* 2006. 66: 286-29
338. Luo J et al. Chronic consumption of short chain FOS does not affect basal hepatic glucose production or insulin resistance in type 2 diabetes. *Journal of Nutrition* 2000. 130: 1572
339. Luo J, Van Yperselle M, Rizkally S et al. Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin-resistance in Type 2 diabetes. *J Nutr* 2000: 130: 1572-7
340. Luo Rizkalla SW, Alamowitch C, Boussairi A, Blayo A, Barry JL, Laffille A, Ouyon F, Bornet FRJ and Salma VS. Chronic consumption of short chain fructooligosaccharides by healthy subjects decreased basal hepatic glucose production but had no effect on insulin stimulated glucose metabolism. *American journal of Clinical Nutrition* 1996. 63: 939-945
341. Macfarlane G and Macfarlane S. Models for Intestinal Fermentation: Association between Food Components, Delivery Systems, Bioavailability and Functional Interactions in the Gut. *Current Opinion in Biotechnology* 2007. 18(2): 156-162
342. Macfarlane GT, Gibson GR and Cummings JH. Comparison of fermentation reactions in different regions of the human colon. *Appl Bacteriol* 1992. 72: 57-64
343. Macfarlane S, Macfarlane GT and Cummings JH. Review article: prebiotics in the gastrointestinal tract. *Aliment Pharmacol Ther* 2006. 24: 701-714

-
344. Majamaa H, Isolauri E, Saxelin M and Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. *J Pediatr Gastroenterol Nutr* 1995. 20: 333–38
345. Mandard S, Zandbergen F, Nguan ST et al., "The direct peroxisome proliferator-activated receptor target fasting induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment," *The Journal of Biological Chemistry* 2004, 279(33): 34411–34420
346. Mani and Tiwari N. Prevalence of obesity and its causative risk factors among young adult females. MSc Thesis. Department of Foods and Nutrition, Vadodara.
347. Mani UV and Mani I. Serum lipids: Triglyceride, cholesterol lipoprotein cholesterol and urinary hydroxyproline levels in insulin dependent and non-insulin dependent diabetes. *J of Clin Biochem Nutri* 1988. 4: 244-248
348. Manichanch C, Rigottier GL, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R et al. Reduced diversity of fecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* 2006. 55: 205-211
349. Marcy Y, Ishoe Y, Lasken RS, Stockwell TB, Walenz BP and Halpern AL. Nanoliter reactors improve multiple displacement amplification of genomes from single cells. *PLoS Genet* 2007. 3: 1702-1708
350. Marion JF. Medical Nutrition therapy for diabetes mellitus and hypoglycemia of non-diabetic origin. Chapter 30. *Krause's food and nutrition therapy*. 12th edition. Saunders Elsevier Publication 2008.
351. Martin FPJ, Sprenger N, Montoliu I, Rezzi S, Kochhar S and Nicholson JK. Dietary modulation of gut functional ecology studied by fecal metabolomics. *Journal of Proteome Research* 2010. 9(10): 5284–5295
352. Martins IJ, Hone E, Foster JK, Sunram SJ, Gnjec A, Fuller SJ, Nolan D, Gandy SE and Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. *Molecular Psychiatry* 2006. 11: 721–736
353. Mastromatteo M, Iannetti M, Civica V, Sepielli G and 'Alessandro Del MN. Effect of the Inulin Addition on the Properties of Gluten Free Pasta. *Food and Nutrition Sciences*, 2012. 3: 22-27
-

-
354. Mat Suzaki T, Nagata Y, Kado S, Uchida K, Hashimoto U and Teruoyokokura. Effect of oral administration of *Lactobacillus casei* on alloxan induced diabetic mice. *APMIS* 2009. 105(7-12): 637-642
355. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, and Drucker DJ. International Union of Pharmacology XXXV. The glucagon receptor family. *Pharmacol Rev* 2003. 55: 167-194
356. Mc Carthy MI. Genomics, type 2 diabetes, and obesity. *N Engl J Med* 2010. 363: 2339-50
357. Mc Ginn S, Saad S, Poronnik P and Pollock CA. High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. *Am J Physiol Endocrinol Metab* 2003. 285: E708-E717
358. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Cortesey I, Mace K and Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. *FASEB J* 2008. 22: 2416-2426
359. Mendlik K, Albrecht JE, Schnepf M. Effects of Fructooligofructoses Chain Length on the *Bifidobacteria* of the Human Colon: A Pilot Study. *Food and Nutrition Sciences* 2012. 3: 1615-1618
360. Menon VU, Kumar KV, Gilchrist A, Sugathan TN, Sundaram KR, Nair V, et al. Prevalence of known and undetected diabetes and associated risk factors in central Kerala - ADEPS. *Diabetes Res Clin Pract* 2006. 74: 289-94
361. Metchnikoff E. *Essais optimistes*. Paris. The prolongation of life. Optimistic studies. Translated and edited by P. Chalmers Mitchell. London: Heinemann, 1907
362. Michael AN. Diabetes as a gut disease. *European Society of Endocrinology* 2012. 29(2): pp. 7
363. Miller CR. *Bifidobacteria* in clinical microbiology and medicine. In Beskorovainy A and Miller-Catchpole R, eds. *Biochemistry and Physiology of Bifidobacteria*. Boca, FL: CRC Press. pp 177-197. 1989
364. Misra A, Khurana L, Isharwal S and Bharadwaj S. South Asians diets and Insulin resistance. *British Journal of Nutrition* 2008. 1-9
365. Misra A, Khurana L, Isharwal S and Bhardwaj S. South Asian diets and insulin resistance. *British Journal of Nutrition* 2009. 101(4): 465-473
-

-
366. Miyazawa E, Iwabuchi A and Yoshida T. Phytate breakdown and apparent absorption of phosphorus, calcium and magnesium in germfree and conventionalized rats. *Nutr Res* 1996. 16: 603-13
367. Modler HW, McKellar RC and Yaguchi M. *Bifidobacteria* and bifidogenic factors- review. *J of Food Sci Technol* 1990. 23: 29-41
368. Mohan V, Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V and Unnikrishnana R et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-India DIABetes (ICMR-INDIAB) study. *Diabetologia* 2011. 54(12): 3022-3027
369. Mohan V, Gokulakrishnan K, Deepa R, Shanthirani CS and Datta M. Association of physical inactivity with components of metabolic syndrome and coronary artery disease - The Chennai Urban Population Study (CUPS No. 15). *Diabetic Medicine* 2005. 22(9): 1206-1211
370. Mojsos S, Heinrich G, Wilson IB, Ravazzola M, Orci L, and Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. *J Biol Chem* 1986. 261: 11880-11889
371. Mokdad AH, Earl S Ford, Barbara A, William H Dietz, Frank Vinicor, Virginia S Bales and James S Marks. Prevalence of Obesity Diabetes and Obesity-Related Health Risk Factors. *The Journal of the American Medical Association* 2003. 289(1): 76-79
372. Molis C, Flourie B, Ouarne F, Failing MF, Lartigue S, Guibert A, Bornet F and Galmiche JP. Digestion, excretion, and energy value of fiuctooligosaccharides in healthy humans. *Am J Clin Nutr* 1996. 64: 324-328
373. Moller PL, Paerregaard A, Gad M, Kristenen NN and Claesson MH. Colitic seid mice fed lactobacillus spp. show an ameliorated gut histopathology and an altered cytokine profile by local T cells. *Inflammatory bowel disease* 2005. 11: 814-819
374. Moreau MC and Gaboriau-Routhiau V. The absence of gut flora, the doses of antigen ingested and aging affect the long-term peripheral tolerance induced by ovalbumin feeding in mice. *Res Immunol* 1996. 147: 49-59
-

-
375. Morgan LM. The role of gastrointestinal hormones in carbohydrate and lipid metabolism and homeostasis effects of gastric inhibitory polypeptide and GLP-1. *Biochemistry Society Transactions*. 1998. 26: 216-222
376. Moro G et al. A mixture of prebiotic oligosaccharide reduces the incidence of atopic dermatitis during the first six months of age. *Arch Dis Child* 2006. 91: 814-819
377. Moroti¹ C, Loyanne Francine Souza Magri¹, Marcela de Rezende Costa and Daniela CU Cavallini¹ and Katia Sivieri^{1,2}. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. *Lipids in Health and Disease* 2012. 11: 29
378. Mortensen K, Christensen LL, Holst JJ, and Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. *Regul Pept* 2003. 114: 189-196
379. Moshfegh AJ, Friday JE, Goldman JP, Chug Ahuga JK. Presence of inulin and oligofructose in the diets of Americans. *J Nutr*. 1999. 129: Suppl 7S: 1407S-11S
380. Muegge BD, Kuczynski J, Knights D, Clemente JC, Gonzalez A and Fontana L et al. Diet Drives Convergence in Gut Microbiome Functions Across Mammalian Phylogeny and Within Humans. *Science* 2011. 332(6032): 970-974
381. Mueller S, Saunier K, Hanisch C, Norion E, Alm L, Midtvedt T et al. Differences in fecal microbiota in different European study populations in relation to age, gender and country: A cross sectional study. *Applied and Environmental microbiology* 2006. 72(2): 1027-1033
382. Muir JG, Rose R, Rosella O, Liels K, Barrett JS, Shepherd SJ and Gibson PR. Measurement of short chain carbohydrates in common Australian vegetables and fruits by High Performance Liquid Chromatography (HPLC). *Journal of Agricultural and Food Chemistry* 2009. 57: 554-565
383. Murphy O. Non-polyol low-digestible carbohydrates: food applications and functional benefits. *British Journal of Nutrition* 2001. 85(1):47-53
384. Murthy VK, Manohar SR and Rao HP. Factors affecting sheeting characteristics of chapati dough using pneumatic pressure extrusion. *Journal of Food Science & Technology* 1998. 35(2): 122-127
385. Mutai M and Tanaka R. Ecology of *Bifidobacterium* in the human intestinal flora. *Bifid Micro* 1987. 6: 33-41
-

386. Namakamura Y, Yamamoto N, Sakai K and Takano T. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin-1-converting enzyme. *J Dairy Sci* 1995. 78: 1253–1257
387. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). *Circulation* 1994. 89: 1333–1345
388. National Family Health Survey III. Prevalence of obesity in India. 2005-06
389. Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, and Creutzfeldt W. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. *J Clin Endocrinol Metab* 1989. 69: 654–662
390. Nauck MA et al. Preserved incretin activity of glucagon like peptide-1 (7-36) amide but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. *J Clin Invest* 1993. 91: 301–307
391. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R and Schmigel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. *Am J Physiol* 1997. 273: E981–E988
392. Nauck MA. Diabetes as a gut disease. *European Society of Endocrinology* 2012. 29: pp. 7 (Abstract)
393. Nauck MA: Is glucagon-like peptide 1 an incretin hormone? *Diabetologia* 1999. 42: 373–379
394. NCD risk factor surveillance study- Chennai chapter, available at: <http://ncd.in/downloads/CHENNAI%20Chapter.pdf> (accessed November 23, 2006)
395. Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, Li J, Cetin S, Ford H, Schreiber A and Hackam DJ. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. *J Immunol* 2006. 176: 3070–3079
396. Nehir S El and Simsek S. Food Technological Applications for Optimal Nutrition: An Overview of Opportunities for the Food Industry. *Comprehensive Reviews in Food Science and Food Safety* 2011. 11: 2-13
397. Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. *Cell Signal* 2008. 20: 2180–97

398. Nian M et al. Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression. *American Journal of Physiology Regulation* 2002. 127:1923
399. Nilsson U and Bjorck I. Availability of cereal fructans and inulin in the rat intestinal tract. *Carbohydrate and Fiber* 1988. 2(4): 1482-1486
400. Nilsson U and Nyman M. Short-chain Fatty Acid Formation in the Hindgut of Rats Fed Oligosaccharides Varying in Monomeric Composition, Degree of Polymerization and Solubility. *British Journal of Nutrition* 2005. 94(5): 705-713
401. Nilsson U, Oste R, Jagerstan M and Birkhed D. Cereal Fructans: In vitro and in vivo studies on availability in rats and humans. *J Nutr* 1988. 118: 1325-1330
402. Niness KR. Inulin and oligofructose: What are they? *J Nutr* 1999. 129: 14025-14065
403. Niranjana G, Arun MS, Srinivasan AR, Muthurangan G, Saha S and Ramasamy R. Association of levels of HbA1c with triglyceride/ high density lipoprotein ratio - an indicator of low density lipoprotein particle size in type 2 diabetes mellitus. *Advance Laboratory Medicine International* 2012. 2(3): 87-95
404. Novoa FJ, Boronat M, Saavedra P, Diaz-Cremades JM, Varillas VF, La Roche F, et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. *Diabetes Care* 2005. 28: 2388-93
405. Nowak B, Von Mueffling T, Grotheer J, Klein G and Watkinson BM. Energy Content, Sensory Properties, and Microbiological Shelf Life of German Bologna-Type Sausages Produced with Citrate or Phosphate and with Inulin as Fat Replacer. *Journal of Food Science* 2007. 72(9): S629-638
406. Nyman M, Pålsson KE, Asp NG and Lebensm WU. *Food Technol* 1987. 20, 29
407. Nyman M. Fermentation and bulking capacity of indigestible carbohydrates. The case of inulin and oligofructose. *British Journal of Nutrition* 2002. 87: S163
408. Nystrom T, Gonon AT, Sjöholm A and Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. *Regul Pept* 2005. 125: 173-7
409. Nystrom T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. *Am J Physiol Endocrinol Metab*. 2004. 287: E1209-15

-
410. O Halloran DJ, Nikou GC, Kreymann B, Ghatei MA and Bloom SR: Glucagon-like peptide-1 (7-36)-NH₂: a physiological inhibitor of gastric acid secretion in man. *J Endocrinol* 1990. 126: 169-173
411. O Hara AM and Shanahan F. gut microbiota: mining for therapeutic potential. *Clinical Gastroenterology Hepatology* 2007. 5: 274-284
412. Ohta A, Ohtsuki M and Hosono A, Adachi T, Hara H, Sakata T. Dietary fructooligosaccharides prevent osteopenia after gastrectomy in rats. *Journal of Nutrition* 1998. 128: 106-110
413. Oku T, Tokunaga T and Hosoya N. Non-digestibility of a new sweetener, "Neosugar," in the rat. *Journal of Nutrition* 1984. 114: 1574-1581
414. Ooi LG and Liong MT: Cholesterol-lowering effects of probiotics and prebiotics: a review of *in vivo* and *in vitro* findings. *Int J Mol Sci* 2010. 11: 2499-2522
415. Orafti 1996. Raftilose and Raftiline. Product book. *Orafti*, Belgium.
416. Orskov C, Wettergren A and Holst JJ: Biological effects and metabolic rates of glucagon- like peptide 1(7-36) amide and glucagon-like peptide 1(7-37) in healthy subjects are indistinguishable. *Diabetes* 1993. 42: 658-661.
417. Osman N, Adawi D, Molin G, Ahrne S, Berggren A and Jeppsson B. *Bifidobacterium infantis* strains with and without a combination of oligofructose and inulin attenuate inflammation in DSS-induced colitis in rats. *BMC Gastroenterology* 2006. 6: 31
418. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. *Gut* 2004. 53: 685-693
419. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. *Diabetes Care* 1997. 20: 537-544
420. Parikh P, Mani UV and Iyer UM. Abdominal adiposity and metabolic control in patients with type 2 diabetes mellitus. *Int J Diab Dev Count* 2002. 22(1): 28-34
421. Parnami S and Sheth M. Determination of β -Fructan in Selected Raw and Processed Indian Foods. *Inventi Rapid: Nutraceuticals* 2010. 1(3): 2010nc054
-

-
422. Parnami S and Sheth M. Indian Fermented Milk (*Dahi*) Fortified with Probiotic Bacteria and Inulin Improves Serum Lipid, Blood Glucose Levels and Gut Microflora. *Journal of The Indian Academy of Geriatrics* 2011. 7: 1-5
423. Parnami S and Sheth M. Inulin as prebiotic in bread and cookies- A feasibility study. *Inventi Rapid: Nutraceuticals* 2010. 1(3): 2010nc055
424. Parnell JA and Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased PYY in overweight and obese adults. *Am J Clin Nutr* 2009. 89: 1751-1759
425. Paul W and Franks. The Complex Interplay of Genetic and Lifestyle Risk Factors in Type 2 Diabetes: An Overview. *Scientifica* 2012 <http://dx.doi.org/10.6064/2012/482186>.
426. Pedersen A, Sandstrom B and Van Amlesvobrt JMM. The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. *British Journal of Nutrition* 1997. 78: 215-222
427. Pedone CA, Bernabeu AO, Postaire ER, Bouley CF and Reinert P. The effect of supplementation with milk fermented by *Lactobacillus casei* (strain DN-114 001) on acute diarrhoea in children attending day care centres. *Int J Clin Pract* 1999. 53: 179-84
428. Penny M. Kris-Etherton. AHA Science Advisory: Monounsaturated Fatty Acids and Risk of Cardiovascular Disease. American Heart Association. *Journal of Nutrition* 2013. pp. 2280-2284
429. Pereira SE, Rubio EM, Pilard S, Mellet CO and Fernández JSM. Di-d-fructose Dianhydride-Enriched Products by Acid Ion-Exchange Resin-Promoted Caramelization of d-Fructose: Chemical Analyses. *Journal of Agriculture Food Chemistry* 2010. 58(3): 1777-1787
430. Perman JA. Gastrointestinal flora: developmental aspects and effects of nutrients. In Leventhal E, Human Gastrointestinal Development. New York: Raven Press, 1989. 777-786
431. Perrin S, Warchol M, Grill JP and Schneider F. Fermentation of fructooligosaccharides and their components by *Bifidobacterium infantis* ATCC 15967 on batch culture in semi-synthetic medium. *J Appl Microbiol* 2001. 90: 859-65
-

-
432. Pessin JE, Thurmond DC, Elmendorf JS, Coker KJ and Okada, S. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. *J Biol Chem* 1999. 274: 2593-2596
433. Piche T, des Varannes SB, Sacher-Huvelin S, Holst JJ, Cuber JC and Galmiche JP. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. *Gastroenterology* 2003. 124: 894-902
434. Pierce M, Keen H and Bradley C. Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. *Diabet Med* 1995. 12: 6-13
435. Piette JD, Heisler M and Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. *Diabetes Care* 2004. 27 (2): 384-391
436. Pilar R. Zeitschrift f r Lebensmitteluntersuchung und -Forschung A 1998. 206(2): 130
437. Playne MJ and Crittenden RG. Galacto-oligosaccharides and Other Products Derived from Lactose. In: PLH. Mc Sweeney PF. Fox, editors. *Advanced Dairy Chemistry*. 3rd ed. New York, NY: Springer. pp. 121-201. 2009
438. Pool-Zobel BL. Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data. *Br J Nutr* 2005. 93: Suppl 1:S73-90
439. Porte D JR. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type-2 diabetes and its complications. *Diab Metab Res Rev* 2009. 17:16-170
440. Poulsen PK, Ohm K, Vaag A, and Beck-Nielsen H. "Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance—a population-based twin study," *Diabetologia* 1999. 42(2):139-145
441. Prapulla SG, Subhaprada V and Karanth NG. Microbial production of oligosaccharides. *Adv Appl Microbiol* 2000. 47:299-343
442. Preter V, Hamer H, Windy K and Verbeke K. The impact of pre/probiotics on human colonic metabolism: Does it affect human health. *Mol. Nutr Food Res* 2011. 55: 46-57
443. Prosky L and Hoebregs H. Methods to determine food inulin and oligofructose. *J Nutr* 1995. 129:14185-14235
444. Pryde S, Duncan S, Hold G, Stewart C and Flint H. The Microbiology of Butyrate Formation in the Human Colon. *FEMS Microbiology Letters* 2002. 217(2) 133-139
-

-
445. Qaisar M, Amara J, Nighat B and Muhammad I. Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus. *Journal of Diabetes* 2012. 4(3): 257-261
446. Qualmann C, Nauck MA, Holst JJ, Orskov C and Creutzfeldt W: Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. *Acta Diabetol* 1995. 32: 13-16
447. Quemener B, Thibault JF, Coussement P. Determination of inulin and oligofructose in food products and integration in the AOAC method for the measurement of total dietary fibre. *Lebensm-Wiss Technol*. 1994. 27: 125-32
448. Quyyumi AA () Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. *Am J Med* 1998. 105: 32S-39S
449. Rabot S, Membrez M and Bruneau A et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. *The Journal of the Federation of American Societies for Experimental Biology* 2010. 24(12): 4948-4959
450. Rafter J, Bennen M, Caderni G, Clune Y, Hughes R, Karlsson PC, Klinder A, O'Riordan M, O'Sullivan GC et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. *Am J Clin Nutr* 2007. 85: 488-96
451. Rahmouni K, Correia MLG, Haynes WG and Mark AL. Obesity-Associated Hypertension: New Insights into Mechanisms. *Hypertension* 2005. 45: 9-14
452. Rajilic-Stojanovic M, Smidt H and De Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. *Environ Microbiol* 2007. 9: 2125-2136
453. Ramachandran A, Jali MV, Mohan V, Snehalatha C and Viswanathan M. High prevalence of diabetes in an urban population in south India. *British Medical Journal* 1988. 297: 587-90
454. Ramachandran A, Snehalatha C, Dharmaraj D and Viswanathan M. Prevalence of glucose intolerance in Asian Indians. Urban-rural difference and significance of upper body adiposity. *Diabetes Care* 1992. 15: 1348-55
455. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. Diabetes Epidemiology Study Group in India (DESI). High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia* 2001. 44: 1094-101
-

-
456. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M. Rising prevalence of NIDDM in an urban population in India. *Diabetologia* 1997. 40: 232-7
457. Ramaiya KL, Kodali VR and Alberti KGMM. Epidemiology of diabetes in Asians of the Indian sub-continent. *Int J Diabetes Dev Ctries* 1991. 11: 15-36
458. Ramulu P and Udayaskhara R P. Plant Foods for Human Nutrition 1997. 50: 249
459. Ranganath LR. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulintropic polypeptide and glucagon-like peptide-1. *J Clin Pathol* 2008. 61: 401-9
460. Ranhotra GS, Gelroth JA and Glaser BK. The role of dairy foods containing bifido - and acidophilus bacteria in nutrition and health? *N Cur Dairy J* 1993. 48:80
461. Rasic IJ, Vujieie LF, Skrinjar M and Vulie M. Assimilation of cholesterol by some cultures of *Lactic acid bacteria* and *Bifidobacteria*. *Biotechnology letters* 1992. 14:39-44
462. Ratner RE, Rosenstock J and Boka G. DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. *Diabet Med* 2010. 27: 1024-1032
463. Rault N, Gueux C, Demougeot C, Demigne ER and Mazur A. Inulin attenuate atherosclerosis in apolipoprotein E deficient mice. *British Journal of Nutrition* 2006. 96: 840-844
464. Ravussin Y, Koren O, Spor A, Leduc C, Gutman R and Stombaugh J et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. *Obesity* 2011 (Silver Spring)
465. Raza S, Graham SM, Allen SJ, Sultana S, Cuevas L and Hart CA. *Lactobacillus* GG promote recovery from acute non bloody diarrhea in Pakistan. *Pediatr Infect Dis J* 1995. 14: 107-11
466. Rebecca Wall1, Paul R, Ross, Fergus S, Eamonn M, Quigley and Timothy G. Influence of gut microbiota and manipulation by probiotics and prebiotics on host tissue fat: Potential clinical implications. *Lipid Technology* 2012. 24(10): 227-229
-

-
467. Reddy KS and Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. *Circulation* 1998. 97: 595-601
468. Reimann F et al. Characterization and functional role of voltage gated cation conductances in the glucagon-like peptide 1 secreting GLUTag cell line. *Journal of Physiology* 2005. 563: 161
469. Reimer RA and McBurney MI. Dietary fibre modulates intestinal proglucagon mRNA and postprandial secretion of GLP-1 and insulin in rats. *Endocrinology* 1996. 137: 3948-3956
470. Renuka B, Kulkarni SG, Vijayanand P and Prapulla SG. Fructooligosaccharide fortification of selected fruit juice beverages: effect on the quality characteristics. *Food Science and technology* 2009. 42: 1031-1033
471. Renuka B, Prakash M and Prapulla SG. Fructooligosaccharides based low calorie gulab jamun: studies on the texture, microstructure and sensory attributes. *Journal of Texture Studies* 2010. 41: 594-610
472. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997. 20: 1183-97
473. Richmand W. Preparation and Properties of a Cholesterol Oxidase from *Nocardia* sp. and Its Application to the Enzymatic Assay of Total Cholesterol in Serum. *Clinical Chemistry* 1973. 19(12): 1350-1356
474. Riedy CA, Chavez M, Figlewicz DP and Woods SC. Central insulin enhances sensitivity to cholecystokinin. *Physiol Behav* 1995. 58: 755-60
475. Riedy CA, Chavez M, Figlewicz DP, Woods SC. Central insulin enhances sensitivity to cholecystokinin. *Physiol Behav* 1995. 58: 755-60
476. Ritzel R, Schulte M, Porksen N, Nauck MS, Holst JJ, Juhl C, Marz W, Schmitz O, Schmiegell WH and Nauck MA: Glucagon like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. *Diabetes* 2001. 50: 776-784
477. Rob M Van Dam, Walter CW, Eric BR and Meir JS. Dietary Fat and Meat Intake in Relation to Risk of Type 2 Diabetes in Men. *Diabetes Care* 2002. 25(3): 417-424
478. Roberfroid M, Gibson GR and Delzenne N. The biochemistry of oligofructose, a nondigestible fiber: An approach to calculate its caloric value. *Nutr Rev* 1993. 51: 137-146
-

-
479. Roberfroid M, Van Loo J and Gibson G. The *Bifidogenic* Nature of Chicory Inulin and its Hydrolysis Products. *The Journal of Nutrition* 1998. 128(1): 11-19
480. Roberfroid M. Fructo-oligosaccharide Malabsorption: Benefit for Gastrointestinal Functions. *Current Opinion in Gastroenterology* 2000. 16(2): 173-177
481. Roberfroid M. Functional foods: concepts and application to inulin and oligofructose. *Br J Nutr* 2002. 87: Suppl 2: S139-43
482. Roberfroid M. Introducing Inulin Type Fructans. *British Journal of Nutrition* 2005. 93(1): 13S-25
483. Roberfroid M. Inulin-type fructans as functional food ingredients. Boca Raton, FL: CRC Press, 2005.
484. Roberfroid MB and Slavin J. Nondigestible oligosaccharides. *Crit Rev Food Sci Nutr* 2000. 40: 461-80
485. Roberfroid MB, Bornet F, Bouley C and Cummings JH. Colonic microflora: nutrition and health: summary and conclusions of an International Life Sciences Institute (ILSI) (Europe)] workshop held in Barcelona, Spain. *Nutr Rev* 1995. 53: 127-30
486. Roberfroid MB, Delzenne N. Dietary fructans. *Annu Rev Nutr* 1998. 18: 117-43
487. Roberfroid MB. Caloric value of inulin and oligofructose. *J Nutr* 1999. 129: 1436S-1437S
488. Roland N, Nugon-Baudon L, Andrieux C and Split O. Comparative study of the fermentative characteristics of inulin and different types of fibre in rats inoculated with a human whole faecal flora. *British Journal of Nutrition* 1995. 74: 239-49
489. Roopa S and Premavalli KS. Effect of processing on starch fractions in different varieties of finger millet. *Food Chemistry* 2008. 106(3): 875-882
490. Root HF and Baker ML. Inulin and artichokes in the treatment of diabetes. *Arch Intern Med* 1925. 36: 126-145
491. Rumessen JJ, Bode S, Hamberge O and Gudmand-Hoyer E. Fructans of the Jerusalem artichokes: intestinal transport, absorption, fermentation and influence on blood glucose, insulin and C-peptide responses in healthy subjects. *Am J Clin Nutr* 1990. 52: 675-681
492. Ryan AS, Egan JM, Habener JF and Elahi D: Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated
-

- glucose uptake in young men during euglycemia. *J Clin Endocrinol Metab* 1998. 83: 2399–2404
493. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of *Bifidobacterium bifidum* and *Streptococcus termophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus. *Lancet* 1994. 334: 1046–49
494. Saito H, Lund-Katz S, Phillips MC. "Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins". *Lipid Res.* 2004. 43(4): 350–80
495. Sakakibara S et al. Acetic acid activates hepatic AMPK and reuces hyperglycemia in diabetic KK-A(y) mice. *Biochemistry Biophysics Research Communication* 2006. 344: 597
496. Salazar P, García ML, Selgas MD. Short-chain fructooligosaccharides as potential functional ingredient in dry fermented sausages with different fat levels. *International journal of food science and technology* 2009. 44(6): 1100–1107
497. Salmeron J, Hu FB et al. Dietary fat intake and risk of type 2 diabetes in women. *Am J Clin Nutr* 2001. 73: 1019–26
498. Salminen S, Bouley C, Bouton-Ruault MC, et al. Functional food science and gastrointestinal physiology and function. *Br J Nutr* 1998; 80 (suppl): S147–71
499. Saltiel AR and Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. *Nature* 2001. 414 (13): 799–806
500. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Ha006Dmer RE, Williams SC, Crowley J, Yanagisawa M, Gordon JI. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G-protein-coupled receptor Gpr41. *Proc Natl Acad Sci U S A* 2008. 105: 16767–16772
501. Sanford PA. Digestive system physiology, 2nd ed., published within a series called Physiological principle in medicine. 2005 Edward Arnold, London
502. Santos BAD, Paulo CBC, Pacheco MT and Pollonio MA. Fructooligosaccharides as a fat replacer in fermented cooked sausages. *International Journal of Food Science and Technology* 2012. 47(6): 1183–1192
503. Sayeed MA, Mahtab H, Khanam PA, Latif ZA, Banu A and Khan AK. Prevalence of diabetes and impaired fasting glucose in urban population of Bangladesh. *Bangladesh Medical Research Council Bulletin* 2007. 33(1): 1–12

-
504. Scardovi V. *Bifidobacterium*. 9th ed. Baltimore, haD: Williams and Wilkins Publishers 2: 1418-1419, 1986
505. Schalkwijk CG and Stehouwer DA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. *Clinical Science* 2005. 109:143-159
506. Schaller LA and Smith DE. Sensory attributes and storage life of reduced fat ice-cream as related to inulin content. *Journal of Food Science* 1999. 64(3): 555-559
507. Scheen AJ. Pathophysiology of type 2 diabetes. *Acta Clin Belg* 2003. 58(6): 335-41
508. Scholz-Ahrens KE and Schrezenmeir J. Inulin, oligofructose and mineral metabolism-experimental data and mechanisms. *British journal of Nutrition* 2002. 87(2): S179-186
509. Scholz-Ahrens KE, Schaafsma G, Van Den EG and Schrezenmeir J. Effects of prebiotics on mineral absorption. *American Journal of Clinical Nutrition* 2001. 73: 459S-464S
510. Schonhoff SE, Giel MM and Leiter AB. Mini review: Development and differentiation of gut endocrine cells. *Endocrinology* 2004. 145: 2639
511. Schumann C. Medical, nutritional and technological properties of lactulose: an update. *European Journal of Clinical Nutrition* 2002. 41(1): 17-11
512. Sethi JK and Vidal-Puig. A Visfatin: the missing link between intra-abdominal obesity and diabetes? *Trends in Molecular Medicine* 2005. 11(8): 344-347
513. Sethi KK. Treatment of Hyperhomocysteinaemia: Emerging issue. *Cardiology today* 2001. 5: 329-333
514. Shah B, Kumar N and Geetha R. Assessment of burden of non- communicable diseases in India: A project supported by WHO India. *Indian Council of Medical Research (ICMR)* 2004. pp. 1-35
515. Shah NP. Natural bioactive substances in milk and colostrum. *British Journal of Nutrition* 2000. 84(S1): S3-S10
516. Shahanan F. Probiotics in inflammatory bowel disease-therapeutic rationale and role. *Advanced drug delivery reviews* 2004. 56: 809-818
517. Shetty P. India's diabetes time bomb. *Nature* 2012. 485(7398): S14-S16
518. Shetty SP. Nutrition transition in India. *Public Health Nutrition*: 5(1A), 175-182. DOI: 10.1079/PHN2001291
-

519. Shin HS, Lee JH, Pestka JJ and Ustunol Z. Growth and viability of commercial *Bifidobacterium* ass in skim milk containing oligosaccharides and inulin. *Food Microbiology and Safety* 2000. 65(5): 884-887
520. Shiyi Ou , Kin-chor Kwok , Yan Li , and Liang Fu. In Vitro Study of Possible Role of Dietary Fiber in Lowering Postprandial Serum Glucose. *J Agric Food Chem* 2001. 49 (2): 1026-1029
521. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. *J Pediatr Gastroenterol Nutr* 1997. 24: 399-404
522. Shornikova AV, Isolauri E, Burkanova L, Lukovnikova S, Vesikari T. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea. *Acta Paediatr* 1997. 86: 460-65
523. Siavoshian S, Segain JP, Kornprobst M, et al. Butyrate and trichostatin A effects on the proliferation/ differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. *Gut* 2000. 46: 507-14
524. Sicree R, Shaw J and Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes Atlas. International Diabetes Federation. 3rd ed. Belgium: International Diabetes Federation. 2006 pp. 15-103
525. Sierra GN. The global pandemic of diabetes: an update. Diabetes pandemic 2009. pp 50-54.
526. Silva RF. Use of inulin as a natural texture modifier. *Cereal Foods World* 1996. 41(10): 792-795
527. Silvester KR, Englyst HN and Cummings JH. Ileal recovery of starch from whole diets containing resistant starch measured in vitro and fermentation of ileal effluent. *Am J Clin Nutr* 1995. 62: 403-11
528. Singh R, Barden A, Mori T and Beilin L. Advanced glycation end-products: a review. *Diabetologia* 2001. 44: 129-146
529. Smith EA and Macfarlane GT. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. *J Appl Bacteriol* 1996. 81: 288-302
530. Snehalatha C, Viswanathan V and Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults. *Diabetes Care* 2003. 26(5): 1380-1384

-
531. Sobota A and Zarzycki P. Effect of Pasta Cooking Time on the Content and Fractional Composition of Dietary Fiber. *Journal of Food quality* 2013. 36(2): 123-137
532. Sridhar GR, Rao PV and Ahuja MMS. Epidemiology of diabetes and its complications. In: RSSDI textbook of diabetes mellitus. Hyderabad: Research Society for the Study of Diabetes in India; pp. 95-112, 2002
533. Stefan P, Massimino, Michael I, McBurney, Catherine JF, Alan Thomson BR, Monika K, Michael GH and Gregory D. Fermentable Dietary Fiber Increases GLP-1 Secretion and Improves Glucose Homeostasis Despite Increased Intestinal Glucose Transport Capacity in Healthy Dogs. *Journal of Nutrition* 1998. 128: 1786-1793
534. Steven M Haffener. Relationship of Metabolic Risk Factors and Development of Cardiovascular Disease and Diabetes. *Obesity* 2006. 14: 121S-127S
535. Stoffers DA et al. Insulinotropic GLP-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. *Diabetes* 2000. 49: 741
536. Strader AD and Wood SC. Gastrointestinal hormones and food intake. *Gastroenterology* 2005. 128: 175-91
537. Stratton IM, Adleander AI, Neil HW, Matthew DR, Manley SE, Cull CA et al. Association of glycemia with macrovascular microvascular complications in type 2 diabetes (UKPDS 35): prospective observational study. *British medical Journal* 2000. 321: 405-412
538. Streppel MT, Arends LR, Vant Veer P, Grobbee DE and Geleijnse JM. Dietary Fiber and Blood Pressure: A Meta-Analysis of Randomized Placebo-Controlled Trials. *Arch Intern Med* 2005. 165: 150-156
539. Sughichi H, Uji O, Okabe H, Irie T, Uekama K, Kayahara N and Miyauchi K. Direct Measurement of High-Density Lipoprotein Cholesterol in Serum with Polyethylene Glycol-Modified Enzymes and Sulfated α -Cyclodextrin. *Clinical Chemistry* 1995. 41(5): 717-723
540. Taguchi H, Takahashi M, Yamaguchi H et al. Experimental infection of germ-free mice with hyper-toxigenic enterohaemorrhagic *Escherichia coli* O157:H7, strain 6. *J Med Microbiol* 2002. 51: 336-43
541. Tahiri M, Tressol JC, Arnaud J, Bornet FRJ, Bouteloup-Demange C, Feillet-Coudray C, Brandolini M, Ducros V, Pe'pin D et al. Effect of short-chain
-

- fructooligosaccharides on intestinal calcium absorption and calcium status in postmenopausal women: a stable-isotope study. *Am J Clin Nutr* 2003. 77: 449-87
542. Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, and Tobe T. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. *Proc Natl Acad Sci USA* 1987. 84: 7005-7008
543. Tannock GW. New perceptions of the gut microbiota: implications for future research. *Gastroenterology* 2005. 12: 44-54
544. Tappenden KA et al. Short chain fatty acid supplemented total parenteral nutrition alters intestinal structure, GLUT2, m-RNA and protein and proglucagon m RNA abundance in normal rats. *Am J Clin Nutr* 1998. 68: 118
545. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. *Diabetes* 1992. 41 Suppl 2: 12-7
546. Taylor DW. The Burden of Non-Communicable Diseases in India, Hamilton ON: The Cameron Institute pp. 13, 2010
547. Thomas C, Auwerx J, Schoonjans K. Bile Acids and the Membrane Bile Acid Receptor TGR5—Connecting Nutrition and Metabolism. *Thyroid* 2008(b). 18: 167-74
548. Thomas C, Pellicciari R, Pruzanski M, Auwerx J and Schoonjans K. Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov* 2008(a). 7: 678-93
549. Thomas G, Hall JE, Appel JL, Falkner BE, Graves J, Hill MN et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. *Circulation* 2005. 111: 697-716
550. Tillin T, Forouhi N, Mc Keigue P, CHaturvedi N. Southall and Brent revisited: cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, India Asian and African Caribbean origins. *International journal of Epidemiology* 2012. 41: 33-42
551. Ting-ning Lin and Gruen I. Sensory analysis, instrumental analysis and consumers' acceptance toward multifunctional ice creams. PhD dissertation. Faculty of the Graduate School, University of Missouri. May 2012

-
552. Toft-Nielsen M, Madsbad S and Holst JJ: The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic gluco regulatory hormones. *Diabetes* 1996. 45:552-556
553. Tomita M, Ohkubo R, Hayashi M. Lipopolysaccharide transport system across colonic epithelial cells in normal and infective rat. *Drug Metab Pharmacokinet* 2004. 19: 33-40
554. Topping D and Clifton P. Short-chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Non-starch Polysaccharides. *Physiological Reviews* 2001. 81(3): 1031-1063
555. Topping D, Fukushima M and Bird RA. Resistant starch as a prebiotic and synbiotic. *Proceedings of the Nutrition Society USA* 2003. 62: 171-176
556. Torregrosa FC, Cortes MJ and Esteve FA. *J Agric Food Chem* 2005. 53, 9519
557. Tsuboi T, da Silva Xavier G, Holz GG, Jouaville LS, Thomas AP, and Rutter GA. Glucagon-like peptide-1 mobilizes intracellular Ca^{2+} and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. *Biochem J* 2003. 369: 287-299
558. Tuohy KM et al. the prebiotic effects of biscuits containing partially hydrolysed guar gum and fructooligosaccharides –A human volunteer study. *British journal of Nutrition* 2001. 86: 241
559. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R and Gordon JI. The human microbiome project. *Nature* 2007. 449: 804-810
560. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, and Gordon JI, "An obesity-associated gut microbiome with increased capacity for energy harvest," *Nature* 2006. 444(7122): 1027-1031
561. Turrone F, Ribbera A, Foroni E, Van Sinderen D and Ventura M. Human gut microbiota and bifidobacteria: From composition to functionality. *Antonie van Leeuw* 2008. 94: 35-50
562. Umesaki Y, Okada Y, Matsumoto S, Imaoka A and Setoyama H. Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo-GM1 glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse. *Microbiol Immunol* 1995. 39: 555-62
563. Umesaki Y, Setoyama H, Matsumoto S, Okada Y. Expansion of alpha beta T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial
-

- colonization in germ-free mice and its independence from thymus. *Immunology* 1993. 79: 32-37
564. Upadhyay PR. An Overview of the Burden of Non- Communicable Diseases in India. *Iranian J Publ Health* 2012. 41(3): pp.1-8
565. Vaidya R and Sheth M. "Resistant starch analysis in raw and processed Indian foods and understanding the mechanism of its action through gut microbiota in Indian diabetics" PhD thesis. Dept. of Foods and Nutrition. The M.S. University of Baroda. December 2011.
566. Van de Wiele T, Boon N, Possemiers S, Jacobs H and Verstraete W. Inulin-type Fructans of Longer Degree of Polymerization Exert More Pronounced in vitro Prebiotic Effects. *Journal of Applied Microbiology* 2007. 102(2): 452-460
567. Van der Waaij LA, Limburg PC, Mesander G and Van der Waaij D. In vivo IgA coating of anaerobic bacteria in human faeces. *Gut* 1996. 38: 348-54
568. Van der Waaij LA. The ecology of the human intestine and its consequences for overgrowth by pathogens such as *Clostridium difficile*. *Annu Rev Microbiol* 1999. 43: 69-87
569. Van Loo J, Coussement P, De Leenheer L, Hoebregs H and Smits G. On the Presence of Inulin and Oligofructose as Natural Ingredients in the Western Diet. *Critical Reviews in Food Science and Nutrition* 1995. 35(6): 525-552
570. Van Loo J, Coussement P, De Leenheer L, Hoebregs H, Smits G. Crit Rev Food Sci Nutr 1995. 35(6): 525
571. Van Loo J, Coussement P, De Leenheer L, Hoebregs H, Smits G. On the presence of inulin and oligofructose as natural ingredients in the Western diet. *Crit Rev Food Sci Nutr* 1995. 35: 525-52
572. Van Loo J, Cummings J and Delzenne N. Functional properties of no digestable oligosaccharides: a consensus report from the ENDO project (DG XII-CT94-1095). *Br J Nutr* 1999. S1: 121-32
573. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA: Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. *Diabetes* 2000. 49: 611-617
574. Venter C, Vorster H and Cummings J. Effects of Dietary Propionate on Carbohydrate and Lipid Metabolism in healthy volunteers. *The American Journal of Gastroenterology* 1990. 85(5): 549-553

-
575. Ventura M, Turrone F, Canchaya C, Vaughan EE. Microbial diversity in the human intestine and novel insights from metagenomics. *Front Biosci* 2009. 14: 3214-3221
576. Ventura M, Van Sinderen D, Fitzgerald GF, Zink R. insights into the taxonomy, genetics and physiology of bifidobacteria. *International Journal of General and Molecular Microbiology* 2004. 86(3): 205-223
577. Videla S, Vilaseca J, Antolin M, Garcia LA, Guarner F, Crespo E et al. Dietary inulin improves distal colitis induced by dextran sodium sulphate in the rat. *American Journal of Gastroenterology* 2001. 96: 1486-1493
578. Vijaykumar G, Arun R and Kutty VR. High prevalence of type 2 diabetes and other metabolic disorders in rural central Kerala. *Journal of the Association of Physicians of India* 2009. 57(3): 563-567
579. Vilsboll T, Krarup T, Deacon CF, Madsbad S and Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. *Diabetes* 2001. 50: 609-613
580. Vinik I and Jenkins A. Dietary Fiber in Management of Diabetes. *Diabetes Care* 1988. 11(2): 160-173
581. Visscher and Seidell. Epidemiology: Definition and Classification of Obesity. *Endocrinology* 2010. DOI: 10.1002/9781444307627.ch1
582. Vivian AF, Ricardo AR, Denis R, Gabor B, Patrick M and John EG. Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. *Diabetes Care* 2012. 35: 1225-1231
583. Voss AC, Maki KC, Garvey WT, Hustead DS, Alish C, Fix B and Mustad VA: Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes. *Nutrition* 2008. 24: 990-997
584. Vuyst de Luk and Leroy F. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifidobacterial competitiveness, butyrate production, and gas production. *International Journal of Food Microbiology* 2011. 149(1): 73-80
585. Wall R, Ross RP, Shanahan F et al. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. *Am J Clin Nutr* 2009. 89: 1393-1401
-

-
586. Wang X and Gibson GR. Effects of the *in vitro* fermentation of oligofructose and inulin by bacteria growing in the human large intestine. *Journal of Applied Bacteriology* 1993. 75: 373
587. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, and Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. *J Clin Invest* 1995. 95: 417-421
588. Wang Z, Xiao G, Yao Y, Guo S, Lu K and Sheng Z. The role of bifidobacteria in gut barrier function after thermal injury in rats. *J Trauma* 2006. 61: 650-657
589. Warburton DE, Nicol C and Bredin S. Health benefits of physical activity: the evidence. *CMAJ* 2006. 174(6): 801-9
590. Waterhouse AL, Chatterton NJ. Glossary of fructan terms. In: Suzuki M, Chatterton NJ, editors. Science and technology of fructans, Boca Raton, FL: CRC Press, pp. 2-7, 1993.
591. Weickert MO and Pfeiffer AFH. Metabolic effects of dietary fiber consumption and prevention of diabetes. *Journal of Nutrition* 2008. 138:439-442
592. Wellen KE and Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005. 115: 1111-1119
593. Welters CFM, Heineman E, Thunnissen BJM, Van den Bogaard AEJM, Soeters PB and Baeten CGMI. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. *Distal Colon Rectum* 2002. 45: 621-627
594. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J and Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. *Dig Dis Sci* 1993. 38: 665-673
595. Weyer C, Bogardus C, Tatarani PA and Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in pathogenesis of type 2 diabetes. *Journal of Clinical investigations* 2001. 104: 787-794
596. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, and Pederson RA. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. *Endocrinology* 1995. 136: 4629 - 4639
597. WHO fact sheet, 2011.
<http://www.who.int/mediacentre/factsheets/fs355/en/index.html>
-

-
598. WHO report. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2011. 34 Suppl 1: S62-9
599. WHO Study Group. Diabetes Mellitus. Technical Report Series no. 727. World Health Organization, Geneva, 1985
600. WHO. Diet, nutrition and the prevention of chronic diseases: Report of a joint WHO/FAO consultation, 2004
601. WHO. Preventing chronic diseases: A vital investment. India fact sheet available from www.who.int/chp/chronic_disease_report/en - accessed on 6 2007
602. Wiggins D and Gibbons F. The lipolysis/esterification cycle of hepatic triacylglycerol. *Biochemistry Journal* 1992. 284(2): 457-462.
603. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004. 27: 1047-53
604. Williams CH, Witherly SA and Buddington RK. Influence of dietary neo sugar on selected bacterial groups of the human fecal microbiota. *Microbiology Ecology Health Disease* 1994. 7: 91
605. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide- 1 receptor stimulation. *Diabetes* 2006. 55: 3387-93
606. Willis CL, Gibson GR, Holt J, Atherton S and Allison C. Negative correlations between oral malodour and numbers and activities of sulphate-reducing bacteria in human mouth. *Archives of oral biology* 1999. 44: 665-670
607. Wilson PWF, Meigs JB, Sullivan L, Fox CS, DM Nathan, and RB Agostino D, "Prediction of incident diabetes mellitus in middle-aged adults: the framingham offspring study," *Archives of Internal Medicine* 2007, 167(10): 1068-1074
608. Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP and Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. *Diabetic Medicine* 2000. 17(1): 40-47
609. Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, Grangette C. Feeding our immune system: impact on metabolism. *Clin Dev Immunol* 2008. 6(3): pp. 9803
-

-
610. Wolver TMS, Brighenti F, Royalle D, Jenkins AL and Jenkins DJA. Effect of rectal infusion of short chain fatty acids in human subjects. *American Journal of Gastroenterology* 1989. 84: 1027-1033
611. Wong J, De Souza R, Kendall C, Emam A and Jenkins D. Colonic Health: Fermentation and Short Chain Fatty Acids. *Journal of Clinical Gastroenterology* 2006. 40(3): 235-243
612. World Health organization (WHO): Diet, nutrition and the prevention of chronic diseases. A joint WHO/FAO. *Expert consultation report* 916, 2003
613. World Health organization (WHO): The world health report- reducing risks, promoting health life. Geneva 2002.
614. World Health Organization. Chronic diseases report, 2005
615. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Department of Non-Communicable Diseases Surveillance, World Health Organization, Geneva, 1999
616. World Health Organization. Demographic trends. In: Health Situation in the South East Asian Region 1998– 2000. Regional Office for South East Asia, New Delhi, 2002. 17–30
617. World Health Organization. Global Health Risks. Mortality and burden of disease attributable to selected major risk factors 2009. WHO press. Geneva. Switzerland. 1-16
618. World Health Organization. Prevalence of Diabetes – World Map. 2008. Available at: <http://www.who.int/diabetes/actionnow/en/mapdiabprev.pdf>. Accessed December 20, 2008
619. World Health Organization. World Health Report, 2004. Changing History. World Health Organization, Geneva, 2004
620. Wren AM, Small CJ, Abbott CR et al. Ghrelin causes hyperphagia and obesity in rats. *Diabetes* 2001; 50: 2540–7
621. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of LPS and LPS-binding protein. *Science* 1990. 249: 1431–1433
622. Wynne K et al. Appetite control. *Journal of Endocrinology* 2005. 184: pp. 291
623. Wynne K et al. Peripheral signals involved in the control of appetite. *Journal of endocrinology* 2005. 184: 291
-

-
624. Xiaokang Wu, Chaofeng Ma, Lei Han, Muhammad Nawaz, FeiGao, Xuyan Zhang, Pengbo Yu, Chang'an Zhao, Lianchuan Li and Aiping Zhou et al. Molecular Characterization of the fecal Microbiota in Patients with Type II Diabetes. *Current Microbiology* 2010. 61(1): 169-178. (Abstract)
625. Xiong Y, Miyamoto N, Shibata K, Valasek MA, Motoike T, Kedzierski RM and Yanagisawa M. Short-chain fatty acids stimulate leptin production in adipocytes through the G-protein coupled receptor GPR41. *Proc Natl Acad Sci USA* 2004. 101: 1045-1050
626. Xu G, Stoffers DA, Habener JF, and Bonner WS. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 1999. 48: 2270-2276
627. Xu J and Gordon JL. "Honor thy symbionts," *Proceedings of the National Academy of Sciences of the United States of America* 2003. 100(18): 10452-10459
628. Yadav H, Jain S and Sinha PR. Oral administration of dahi containing probiotic lactobacillus acidophilus and lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. *Journal of Dairy Research* 2008. 75: 189-195
629. Yamada S. ^{45}Ca kinetics and balance study. A useful method for analysing the effects of drugs on calcium metabolism. In: Ogura H, editor. Pharmacological approach to study the formation and the resorption mechanism of hard tissues. Tokyo: EuroAmerica Publishers, pp. 75-92, 1994
630. Yamashita K, Kawai K and Itakura K. Effect of fructooligosaccharides on blood glucose and serum lipids in diabetic subjects. *Nutr Res* 1984. 4: 961-6
631. Yan F and Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. *Journal of biological chemistry* 2002. 277: 50959-50965
632. Yasuda K, Ronekar KR, Miller DD, Welch RM, Lei XG. Supplemental dietary inulin affects the bioavailability of iron in corn and soybean meal to young pigs. *Journal of Nutrition* 2006. 136: 3033-3038
633. Yokoyama WH, Hudson CA, Knuckles B, Chui M-CM, Sayre RN, Turnlund JR and Schneeman BO: Effect of barley beta-glucan in durum wheat pasta on human glycemic response. *Cer Chem* 1997. 74: 293-296
634. Yoshino G, Hirano T, Kazumi T. Dyslipidemia in diabetes mellitus. *Diabetes Research Clinical Practice* 1996. 33: 1-14
-

-
635. Younes H, Coudray C, Bellanger J, Demigne C, Rayssiguier Y and Remesy C. Effects of two fermentable carbohydrates (inulin and resistant starch) and their combination on calcium and magnesium balance in rats. *Br J Nutr* 2001. 86: 479-85
636. Yu M, Moreno C, Hoagland KM et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. *J Hypertens* 2003. 21: 1125-35
637. Zargar AM, Masoodi SR, Laway BA, Khan AK, Wani AI, Bashir MI and Akthar S. Prevalence of obesity in adults- an epidemiological study from Kashmir valley of Indian subcontinent. *J Assoc Physicians India* 2000. 48: 1170-4
638. Zemel MB. Calcium Modulation of Hypertension and Obesity: Mechanism and Implication. *J Am Coll Nutr* 2005. 20: 428S-435S
639. Zhou J, Wang X, Pineyro MA, and Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin producing cells. *Diabetes* 1990. 48: 2358-2366
640. Zimmet P, Alberti KG and Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 2001. 414(13): 782-787
641. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the doomsday scenario be averted? *J Intern Med* 2000. 247: 301-310.
642. Zoetendal EG, Rajilic-Stojanovic M and De Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. *Gut* 2008. 57: 1605-1615
643. ZR Xu, CH Hu, MS Xia, XA Zhan and MQ Wang. Effects of FOS on digestive enzyme activities, intestinal microflora and morphology of male broilers. *Poultry science* 2003. 82: 1020-1036
-